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Abstract
As medical device manufacturers operating in the Asia-Pacific region are planning for increased demand
in the near future, they must evaluate their manufacturing footprint strategies to determine if they are
getting the most value out of their supply chains given the various incentives and costs associated with
regional manufacturing. Company X is investigating manufacturing expansion opportunities for medical
devices due to the significant revenue growth rates expected for the Asia-Pacific region, especially in the
emerging markets. This thesis deals with the development of a repeatable methodology that can be used
to evaluate various medical device products and manufacturing capabilities for Asia-Pacific sourcing. The
methodology was tested on a selected subsidiary to determine if a regional manufacturing opportunity
exists. Furthermore, a business process, which includes insights into data collection, team formation, and
implementation of footprint decisions, was developed for Company X to use in determining its overall
network strategy for the sector. Other manufacturers can apply the methodology and the business process
in the development of their manufacturing footprint strategies as well. Although the results from the
decision analysis did not favor expansion of the manufacturing operations for the selected Product Line B
in the Asia-Pacific region, they helped in identifying the key factors that would favor regional expansion.
In addition, crucial factors that may be difficult to quantify, such as intellectual property rights, must be
considered before making a expansion decision, even if it is the favored outcome based on the results of
the decision analysis for other product lines or subsidiaries.
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1 Introduction
This chapter defines the problem statement and presents the research methodology used in the
evaluation of the problem, objectives of the evaluation, and an overview of both Company X and the
medical device industry. The chapter summary, which is presented in the last section, provides an outline
of the entire thesis.
1.1 Problem Statement
With the expected growth of the medical device industry in the Asia-Pacific region, especially in
emerging markets such as China and India, many manufacturers are developing strategies to take full
advantage of the situation from a supply chain perspective. Company X, in particular, is assessing the
risks and benefits of increasing the regional presence of its manufacturing and supply chain operations in
order to increase its responsiveness to market demands more rapidly. The goal of this project was to
develop a repeatable methodology and a business process that can be used to evaluate medical device
products and manufacturing capabilities exploiting regional sourcing opportunities. The developed
methodology was tested on a selected range of products from a subsidiary of Company X to determine if
a regional manufacturing opportunity exists with the given forecasts as well as various uncertainties.
1.2 Research Methodology & Objectives
In order to develop a repeatable methodology and an appropriate business process, a variety of
sources were used. Research literature reviews and stakeholders interviews were used to identify the key
criteria needed to determine what products are suitable for manufacturing in Asia-Pacific, the method of
production (i.e., internal manufacturing or outsourcing), and how to evaluate locations for manufacturing
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operations. The macroeconomic and project risk factors that should be accounted for in the decision
analysis were also identified in a similar manner. In a parallel effort, the product lines for a selected
franchise were evaluated using the risk factors, sales, and capacity forecasts to determine if manufacturing
opportunities existed in various regional locations and what the best option for expansion would be in
various scenarios. In addition, an evaluation of a key process technology used by Company X was
completed to illustrate an example for determining when a process technology is considered a trade secret
and what steps should be taken to protect intellectual property (IP). The research conducted was
completed in order to meet the following objectives:
- Determine the key decision factors needed from a manufacturing footprint strategy in the Asia-
Pacific region and incorporate them into a repeatable methodology
- Formulate a business process to show how the decision factors should be treated in order to make
informed decisions for manufacturing footprint decisions
- Demonstrate how various decision analysis tools (e.g., net present value calculations, landed cost
analysis, sensitivity analysis) can be used to identify the best option(s)
- Identify the considerations for determining products and processes with IP sensitivity and
illustrate how they can be applied, with a case example using a current process technology
- Provide recommendations and topics for further evaluation based on the research conducted and
outcomes
1.3 Company Overview
Company X is a diversified health care company that operates in more than 60 countries
worldwide. The company develops, manufactures, and markets a variety of products ranging from
pharmaceutical products to orthopedic devices. It is made up of a number of subsidiaries, each of which is
responsible for developing and marketing a distinct set of products.
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Company X's organizational structure is primarily based on the decentralized principle for
management. Each of the primary subsidiaries used to operate independently and manage their own
revenues and costs. However, in 2010, the primary manufacturing and supply chain operations for each of
the subsidiaries were removed from their respective organizations and re-organized into a separate
division. This organization works with the different subsidiaries to ensure product supply, develop
strategies to reduce operating costs, and mitigate supply risks. Executive leaders anticipated that the shift
would significantly help in aligning all of the manufacturing and supply chain operations to similar
quality standards throughout the network and improve end-customer relationships overall. For each of the
three major product divisions (denoted as Divisions A, B, and C in this thesis), there is an executive
leader and team responsible for the manufacturing and supply chain operations of that business segment.
Figure 1 provides a high-level overview of the organizational structure for the Company X's new supply
chain division as follows (note: this organizational chart only includes the groups within the division that
are referenced in this thesis, and there are other groups that are not included in this figure):
Figure 1 - High-Level Organizational Structure of the Supply Chain Division
The Division A Supply Chain Group is responsible for these operations across the medical device
subsidiaries. This group is referred to as "the" Supply Chain Group throughout this thesis. There are also
a number of groups that support various other functions in addition to the Supply Chain Group, including
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Finance, Legal Affairs, and Human Resources (HR). In addition, each subsidiary has retained various
manufacturing and supply chain personnel to coordinate efforts between the Supply Chain Group and the
various commercial (i.e., sales and marketing) and Research & Development (R&D) functions for that
subsidiary. This group is called the Subsidiary Operations Development Group and resides within the
subsidiary.
1.4 Industry Overview
Although medical devices have existed for centuries, the industry has only been recognized
within the last century. The U.S. Food and Drug Administration (FDA), which is the regulatory agency
for medical devices and diagnostics in the United States, defines a medical device as "an instrument,
apparatus, implement., in vitro reagent, or other similar or related article, including a component part, or
accessory, which is:
e recognized in the official National Formulary, or the United States Pharmacopoeia, or any
supplement to them,
- intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation,
treatment, or prevention of disease, in man or other animals, or
" intended to affect the structure or any function of the body of man or other animals, and which
does not achieve any of its primary intended purposes through chemical action within or on the
body of man or other animals and which is not dependent upon being metabolized for the
achievement of any of its primary intended purposes." (Food & Drug Administration, 2012)
Medical devices include a variety of products ranging from sutures to blood glucose monitors and
orthopedic implants. Diagnostics are also included under this definition. While the FDA is one of the
oldest and most respected regulatory agencies of its kind, most countries have their own rules and
regulations for the manufacturing, marketing, and distribution of medical devices within its territories.
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The global market for the medical devices industry was valued at nearly $238 billion in 2011 and is
expected to grow 5.1% annually till 2015 (Frost & Sullivan, 2012).
1.5 Chapter & Appendix Summary
The following is a summary of the chapters and appendices that are included in this thesis
document:
* Chapter 2 provides details of the project motivation, focusing on the expected growth in the Asia-
Pacific region, Company X's current supply operations in the region, and the need for both a
methodology and a business process.
e Chapter 3 describes the methodology that can be applied in determining what products are
suitable candidates for regional sourcing, where the products could be manufactured, and how
supply operations should be considered. Given the decisions made in each segment, decision
analysis tools can be applied in order to determine the best path forward.
- Chapter 4 gives an overview of the business process that medical device manufacturers can use in
applying the methodology and how to organize and manage the process. An overview of how the
business process can be applied at Company X is also shown.
- Chapter 5 provides insights to the IP rights and considerations that should be made when
considering a manufacturing expansion in the Asia-Pacific region. This chapter focuses on trade
secret protection, and an example of a process technology at Company X is evaluated. In
addition, the chapter has an overview of the valuation of a trade secret loss.
- Chapter 6 includes a case study in which the methodology is applied to product lines of a
subsidiary at Company X. In addition to applying the tools, the results of the decision analysis are
provided along with a sensitivity analysis.
16
- Chapter 7 builds on the results from the case study to provide further considerations in the
manufacturing footprint strategy development sphere and potential next steps for the Supply
Chain Group at Company X.
* Appendix A lists all equations, uncertainties, and risk factors that were applied during the case
study.
Appendix B includes the data set(s) that were analyzed as part of the case study as well as
summary notes for each of the decision analysis tools.
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2 Project Motivation
This chapter addresses why Company X and other medical device manufacturers are interested in
expanding its supply chain operations in the Asia-Pacific region. The motivation for this project should be
viewed as the first step in the development of the regional manufacturing footprint strategy as discussed
by Christodoulou, Fleet, Hanson, Phaal, Probert, & Shi (2007). Figure 2 highlights "why" a medical
device manufacturer would want to develop a manufacturing footprint strategy in the Asia-Pacific region
(original figure from Christodoulou et al., 2007, p. 10):
e Market Demand
- Build Customer Relationships & Supply Chain Responsiveness
- Government Incentives
- Potential to Spur Innovation & Take Advantage of Existing Technical Capabilities
- Financial Incentives
Why?
How? What?
Where?
Figure 2 - "Why" to Develop a Location-Specific Manufacturing Footprint Strategy
In this chapter, we review the expected regional market growth and briefly assess the Supply Chain
Group's current regional operations. Then, we evaluate the benefits and the risks of the Asia-Pacific
expansion opportunities based on literature research and interviews with key stakeholders across
Company X. This evaluation leads to the need for a repeatable methodology and a rigorous business
process for the group. Further details of the applied methodology ("What", "Where", and "How") are
discussed in Chapter 3.
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2.1 Market Growth in the Asia-Pacific Region
Company X is very interested in increasing its market access for the Asia-Pacific region based on
the anticipated growth rates, especially in emerging markets such as China and India. Figure 3 illustrates
the expected growth of the medical device industry in the Asia-Pacific region compared to the rest of the
world (Frost & Sullivan, 2012):
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Figure 3 - Worldwide Medical Device Market Outlook till 2015
The medical device industry in Asia-Pacific is expected to grow at a cumulative annual growth rate
(CAGR) of 11.6% till 2015, which is more than double the global growth rate of 5.1%. Based on the
same report, the Asia-Pacific region will account for 33.2% of the global medical device market in 2015.
The primary growth drivers are an aging population and access to new surgical options for patients in
these markets (Frost & Sullivan, 2012).
Within the Asia-Pacific region, the developing markets are expected to have the highest growth
rates as evidenced in Figure 4 below (Frost & Sullivan, 2012):
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Figure 4 - Medical Device Market Outlook in the Asia-Pacific Region till 2015
While Japan is expected to maintain the highest market share, China is expected to grow significantly
over the next few years. Although these figures may change due to a potential economic slowdown, the
developing nations in the Asia-Pacific region will still likely grow at faster rates than its developed
counterparts. In order to enhance market share, Company X is developing medical devices that are geared
specifically for the needs of those customers.
Donoghoe, Gupta, Linden, Mitra, and Von Morgenstern (2012) argue that companies attempting
to market and sell their current product lines in developing markets have not been as successful as
anticipated. The customer needs in the developing countries, especially the suburban and rural areas, are
different from what a company's traditional offerings are, and product cost still remains a key driver. In
2008, various subsidiaries within Company X embarked on an R&D project to develop low-cost medical
devices that would meet these customers' needs. Aptly nicknamed "market-appropriate products", they
are currently being developed, tested, and sold in China. One of the differences between the market-
appropriate products and the original products being sold include the use of metal parts in order for
devices to be cleaned, sterilized, and re-used. Company X is paying particular attention to whether it is
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more appropriate to manufacture these products closer to its intended customers as part of its Asia-Pacific
manufacturing footprint strategy. This is in addition to other devices with similar manufacturing
platforms that could also be produced using the same unit operations.
2.2 Current Medical Device Supply Operations in the Region for Company X
The Supply Chain Group currently has a limited presence in the Asia-Pacific region when
compared to its presence in North America and Europe. The following is a list of the internal medical
device and diagnostic manufacturing sites in the Asia-Pacific region and the main product lines produced
at each location:
- China - Implants & Medical Devices
- India - Liquids & Medical Devices
- Pakistan - Liquids & Medical Devices
" Japan - Liquids
Less than 5% of the medical devices and diagnostics sold in the region are manufactured at all of
these facilities combined. Of the current locations, the Supply Chain Group generally sees the most
opportunities for expansion at its current sites in China and India. In addition to potentially developing its
internal manufacturing capabilities, the group will also be expanding its regional distribution center in
Singapore over the next two years. Singapore was chosen because of the number of company executives
that currently work in the country and the opportunity to gain broader access to the Asia-Pacific markets
in general. The plan is to manage the inventory for the entire region from a single location rather than rely
on multiple distribution centers. As a result, the medical device manufacturing sites in the internal
network will be required to send all manufactured products to the Singapore location, even if it means that
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some of those products will be sold in the country of manufacture. This strategy could be reevaluated with
additional changes to the regional manufacturing footprint.
The Supply Chain Group has relationships with a number of suppliers and third-party
manufacturers in the region. Certain subsidiaries, however, have more ties to suppliers and contract
manufacturers in the Asia-Pacific region than others. Although the group is not actively expanding its
regional supplier base at this time, it is working with its current regional suppliers to minimize costs and
ensure quality. For example, the External Operations Group, which is responsible for managing third-
party manufacturing within the Supply Chain Group, is looking into the possibility of establishing a
branch location in the Asia-Pacific region to strengthen its relationships with its regional contract
manufacturers. While the primary focus of this thesis is on the internal manufacturing footprint strategy
development, the potential outsourcing opportunities are also taken into consideration where appropriate.
2.3 Benefits & Risks to Manufacturing Medical Devices in the Asia-Pacific Region
Across Company X, there are different views as to benefits and risks of conducting
manufacturing operations in the Asia-Pacific region. In order to gain a better understanding of the various
views, I conducted 23 interviews with key stakeholders that were involved in the analysis of regional
opportunities. They were asked to identify the benefits and risks of having a manufacturing presence in
the Asia-Pacific region. These factors are integrated into the methodology presented in Chapter 3. The
potential benefits of manufacturing in the region, as identified through the various interviews and
subsequent literature research, are as follows:
1. Build Stronger Customer Relationships & Supply Chain Responsiveness
In the past, Company X has been successful at developing strong relationships with customers
and regulatory agencies by establishing a manufacturing presence in various locations. Such a
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presence allowed them to make process modifications based on customer input much faster. For
example, an operations leader overseeing the medical device manufacturing strategy for the Asia-
Pacific region noted that there could be potential changes to labeling requirements as part of
Chinese State Food and Drug Administration (SFDA) Regulation 276 in 2013 that would require
devices to be labeled in the appropriate language prior to being shipped to China. Most labels are
currently placed on product boxes at a facility in China. Having an existing facility in the region
that can conduct labeling operations outside of China would ease the burden of meeting this
requirement if the change were instituted. While decreases in lead time and a reduced probability
of local stockouts can occur due to proximity of the manufacturing and distribution facilities,
much of it is also dependent on supplier locations and their ability to meet demand at each
manufacturing location.
2. Government Incentives
Currently, there are no governments in the Asia-Pacific region that require a company to have a
local manufacturing presence in order to market and sell products in that country. However, there
is no guarantee that this precedence will not change over time. For example, as part of its Pharma
2020 Plan, the Russian government is requiring pharmaceutical and medical device companies to
domestically manufacture at least 50% of the products that it intends to sell in the country (Frost
& Sullivan, 2011). In addition, governments could always increase duties on imported medical
devices in an effort to promote in-country manufacturing. Company X would be in a better
position if a manufacturing presence were already established and such actions were taken.
3. Potential to Spur Innovation & Take Advantage of Existing Technical Capabilities
Company X has established R&D centers in China and India to help in the development of
market-appropriate products. Two senior manufacturing managers believe that having a
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manufacturing presence will have a similar effect on innovation. Moreover, two stakeholders are
strong advocates of the Supply Chain Group taking advantage of the current technology centers
of excellence in the region as part of the manufacturing footprint strategy.
4. Financial Incentives
The traditional incentives for manufacturing in certain locations in the Asia-Pacific region include
lower labor and overhead costs in certain countries (e.g., parts of China and India). Furthermore,
if fuel prices continue to increase, local manufacturing could lead to lower transportation costs
and become yet another incentive. Company X is focusing their efforts on regional market access
with costs savings being a secondary consideration.
While these benefits could certainly help any medical device manufacturer, they are not without
various risks. The same stakeholders identified the following risks in the regional footprint development
process:
1. Developing Talent & Operating Capabilities in the Region
Since the Supply Chain Group does not have a strong regional presence, there will need to be
significant investments in building facilities and developing management talent. Six of the 18
stakeholders interviewed from the group pointed to the difficulty with developing and retaining
talent in China due to the high turnover rate. Moreover, this is not unique to Company X. Powell
(2012) notes that some companies in the biotech and pharmaceutical industries currently have
turnover rates close to 50% at their locations in China.
2. Changing Regulations in Countries Throughout the Region
The regulatory agencies in the region have not been in existence as long as agencies such as the
U.S. FDA. Consequently., they are still developing their policies with respect to device
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registration and trial requirements. Sixteen of the 23 stakeholders interviewed across Company X
specifically commented on the clinical trial requirements in China as a barrier to entry. Based on
the current interpretation of the rules from the SFDA, a majority of Class II products will require
clinical testing through trials if the devices are manufactured in China with the intention of selling
and distributing them in the country. However, this rule does not apply for the same devices that
are manufactured elsewhere (i.e., outside of China) and then exported there for commercial
purposes. The same group of stakeholders also noted that this rule could be changed by the SFDA
at any time.
3. Intellectual Property Rights
Even though there are countries in the Asia-Pacific region with strong IP protection in general,
the same cannot be said for many developing countries in the region with the higher expected
growth rates. Company X is very cautious of placing processes required strong IP protection in
certain countries. This issue is explained in greater detail in Chapter 5.
2.4 The Need for a Methodology and a Business Process
Given the expected revenue growth and the limited medical device manufacturing presence in the
Asia-Pacific region, the Supply Chain Group is looking for a way to evaluate its manufacturing
opportunities to determine if it makes sense to source certain medical devices from the region. On the
other hand, it could be more cost-effective and beneficial to continue sourcing products from current
manufacturing locations in its network. In order to make the best decisions, a comprehensive and
repeatable methodology must be used. In the past, each of the primary subsidiaries at Company X was
responsible for investigating its own manufacturing opportunities, and a standardized method was not
applied. Opportunities that did not appropriately account for certain macroeconomic factors or combined
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facility capabilities during the analyses may have been overlooked as a result. The methodology reported
in this thesis takes into account the benefits and risks with manufacturing in the region in order to make
the best decision. Further details regarding the risk factors to incorporate and analyze are explained in
Chapter 3.4.
In addition to using a repeatable methodology, a business process is developed in order to
standardize the way that the methodology was followed. It includes insights into data collection, team
formation, review timeframes, and implementation of footprint decisions when following the
methodology. Some of the existing decision tools at Company X can be incorporated in the business
process. Further details about the process are discussed in Chapter 4.
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3 A Methodology for Developing a Manufacturing Footprint Strategy
The methodology proposed in this chapter is structured similarly to the framework recommended
by the Institute for Manufacturing at the University of Cambridge but is tailored for developing the
footprint strategy in the Asia-Pacific region as opposed to a company's entire network. The "Why-What-
Where-How" framework, as depicted in Figure 5 below, can be used to identify the possible footprint
expansion options in the region (original figure from Christodoulou et al., 2007, p. 10):
- Build Customer Relationships & Supply
Chain Responsiveness
- Market Demand
* Government Incentives
e Financial Incentives
- Considerations - Demand
for Outsourcing Why? Capacity
Manufacturing How? What? - Process
Operations Complexity
e Value Chain Where? * Cost & Time
Analysis Benefits
e Operating Capabilities
e Ability to Meet Government & Regulatory
Requirements
e Political & Environmental Stability
* Cost Implications
Figure 5 - Overview of the Methodology for a Medical Device Manufacturer
The "Why" part of the framework was explained in Chapter 2 as part of the company's need for the
manufacturing footprint strategy in the Asia-Pacific region. The following subchapters include the
structure for determining 1) what products are candidates for regional sourcing, 2) where manufacturing
should take place, and 3) how the supply chain should be developed. My research with Company X
helped me to develop the specific criteria for the "What" and "Where" phases. Each section includes a
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modified version of Figure 5 that details the decision criteria for each phase. The specific risk factors and
uncertainties to account for are also described throughout the chapter. Using the methodology should
yield a variety of options with a number of manufacturing solutions. At that point, a decision analysis will
be required to select the most appropriate choice. Insights into the decision analysis tools are given in the
last section of this chapter.
3.1 Decision Criteria for What Products to Source
The first step is to determine what products are most suitable for sourcing in the Asia-Pacific
region. The objective is to identify candidates that could be manufactured successfully in the region from
a variety of products using the criteria highlighted in Figure 6 below (original figure from Christodoulou
et al., 2007, p. 10):
- Demand
- Capacity
- Process Complexity
- Regulatory Classification
- IP Rights
- Process Maturity
W hy? W t Operating Capabilities
w What?- Required
- Investment Required
Where? Cost & Time Benefits
- Decreased Lead Times
- Proximity to Suppliers
- Lower Operating Costs
- Lower Logistics Costs
- Tax Benefits
Figure 6 - Decision Criteria for the "What" Analysis
The following is a list of criteria, developed through my industry and company research, that should be
examined when evaluating a variety of products as part of the manufacturing footprint strategy
development:
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1. Regional & Global Demand
It is important to examine country-specific and Asia-Pacific demand to understand what the
customer's needs are. Global demand should also be evaluated since it is likely that the new
manufacturing facility could meet production needs to satisfy demand in other regions
worldwide. Each of the subsidiaries at Company X annually creates a 7-year forecast of global
and regional sales, and some subsidiaries provide sales forecasts by country. Appendix A
includes an example of how the sales forecast can be translated into forecasts for demand volume
(i.e., the number of units to be manufactured). Variations in both the sales and demand volume
forecasts must be considered in evaluating the criterion, and they should be taken into account as
part of the decision analysis. For example, large variations in the sales forecasts could yield
situations where demand volume is lower than expected. Consequently, the decision to expand
may not be the most suitable one.
2. Current Network Capacity
While evaluating product demand, it is also important to understand the capacity constraints at
existing manufacturing locations in the network. The Supply Chain Group began translating the
sales forecast data into demand volume forecasts and line utilization forecasts in 2012 with the
expectation of identifying capacity needs as early as possible. Given the significant investment
needed for a new facility, it generally is not worthwhile to build a new plant if an existing plant
can meet demand over the forecast horizon with a lower investment cost. While capacity may
exist in the network, products that are single-sourced (i.e., produced in only one location) could
be viewed as a supply chain risk, especially if another backup location is not identified or
available. This is another risk that should be accounted for in the decision analysis. Treleven and
Bergman (1988) go into further detail regarding the benefits and costs and risks associated with
single sourcing and dual sourcing.
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3. Process Complexity
The required skill sets and processing needs vary among the range of product lines supported by
the Supply Chain Group. The following are the criteria that should be evaluated for determining
how complex it would be to complete the technology transfer and conduct manufacturing
operations:
- Regulatory Classification - More work is generally required for devices with higher
classifications. As an example, clinical trials may be required for Class 3 devices, as
classified by the FDA, produced in a new location. In general, the Medical Device
Supply Chain Group is more cautious about establishing manufacturing locations for
Class 3 devices than Class 2 or Class 1 devices for this reason.
- IP Rights - It will be more difficult to transfer manufacturing processes that are
considered to be trade secrets to certain locations in the Asia-Pacific region for fear of IP
theft and possible counterfeiting. This is further discussed in Chapter 5.
- Process Maturity - Mature processes are generally characterized as those having higher
and more stable yield rates, strong product and supply specifications, and minimal quality
issues previously. These processes are more likely to be transferred successfully based on
previous experience within the Supply Chain Group.
e Operating Capabilities Required - There are certain processes that may require trained
expertise in order to conduct manufacturing. For instance, if a process involves training
in a new skill set such as those required for biologics manufacturing, there may be a
stronger need for operator capabilities (e.g., operators with technical backgrounds). On
the other hand, several mechanical assembly processes used by the Supply Chain Group
at various facilities do not require the same level of operating capabilities.
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* Investment Required - The potential cost benefits (described below in Item 4) or
potential revenue gain must at least make up for the initial investment. For the Supply
Chain Group, different process technologies require different levels of investments. This
criterion becomes considerably more important if capital is constrained in various
organizations and only a certain combination of product lines is initially selected.
4. Cost & Time Benefits
There should be some major benefits to manufacturing the product in the Asia-Pacific region
relative to the current manufacturing operations or, if it is a brand-new product line, where the
products are initially developed (e.g., R&D facilities). The following is a list of the potential
benefits that should be evaluated:
- Decreased Lead Times - With a new location in the region, there is an opportunity to
decrease the lead times for raw material supply to the facility and finished goods to
customers.
* Proximity to Suppliers - If the raw material suppliers for the devices being evaluated
have operations in the region, there is an opportunity to strengthen relationships and
potentially reduce material costs. In the past, some suppliers have located new supply
operations close to the Supply Chain Group's manufacturing facilities. This could happen
again if the Supply Chain Group were to expand its manufacturing footprint in the Asia-
Pacific region.
- Lower Operating Costs - This refers to the general expenses of conducting
manufacturing operations in that location, such as labor, and overhead, while accounting
for the appropriate risks (e.g., long-term currency variation)
- Lower Logistics Costs - By producing those products in the region and not having to
rely on imports, there are opportunities to take advantage of lower raw material and
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finished goods transportation costs. A producer could also take advantage of reductions
in import taxes and duties through free trade agreements. Further evaluation of this
potential advantage as discovered in the case study is presented in Appendix A.
Tax Benefits - As previously mentioned, certain locations provide income tax incentives
to companies that establish manufacturing locations there. While countries such as
Singapore have low corporate tax rates in general, countries such as Malaysia offer short-
term tax benefits to incentivize multinational corporations to establish a manufacturing
presence (Ernst & Young, 2012). However, in certain situations, it may not be beneficial
overall for a medical device manufacturer to take advantage of the tax incentive based on
its overarching income tax strategy.
When evaluating the criteria above, there will likely be some overlap between the location choices and
how operations should be conducted once the potential product lines are identified. These overlaps are
discussed in more detail in Chapters 3.2 and 3.3.
3.2 Decision Criteria for Where to Conduct Operations
Once the products that could be successfully manufactured in the Asia-Pacific region are
identified, the next step is to consider where manufacturing should take place. The objective is to identify
potential locations where manufacturing should take place using the criteria as highlighted in Figure 7
below (original figure from Christodoulou et al., 2007, p. 10):
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Why?
How? What?
Where?
* Operating Capabilities
- IP Protection
- Technology & Talent Availability
- Availability of Supplier & Key
Contractors
- Language & Cultural Barriers
- Ability to Meet Government & Regulatory
Requirements
- Political & Environmental Stability
- Cost Implications
Figure 7 - Decision Criteria for the "Where" Analysis
The following is a list of criteria developed by myself through my research with Company X that
should be evaluated when choosing locations as part of the manufacturing footprint strategy development:
1. Operating Capabilities
This is the most important criterion when determining a location, based on the research conducted
with the Supply Chain Group. In order to ensure quality, the right capabilities must be present. It
is possible for medical device manufacturers to develop certain capabilities in remote locations
over time, but there are distinct advantages to choosing locations where the infrastructure already
exists. The following is a list of considerations to review when looking at the general operating
capabilities of a potential location:
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- IP Protection - If a product identified in the first stage of the methodology as a potential
candidate has a process that is a trade secret, it should be placed in locations that have a
reputation for strong IP protection. This is discussed in greater detail in Chapter 5.
- Technology & Talent Availability - Certain locations are attractive for their
prominence in technology platforms and worker talent. The leadership team of the
Supply Chain Group believes that it is likely to find greater success in establishing a
manufacturing presence in these types of locations. Steinle and Schiele (2007) explain
that firms that establish locations in industry clusters "can benefit from an increased
availability of complementary products and services and have better access to suppliers,
specialized employees in the local labor pool, specific information and public institutions,
such as specialized education or associations" (p. 4). In addition, during the various
stakeholder interviews, many stakeholders expressed an appreciation for the campus
approach in establishing manufacturing locations. This entails having a variety of
manufacturing processes and technologies, which are utilized to produce devices for a
range of subsidiaries, in a specified location to leverage operating capabilities overall.
The stakeholders in the Supply Chain Group view its campus in Mexico as highly
successful for this reason. Therefore, there is a greater emphasis to establish
manufacturing operations at sites where the company already has a presence.
- Availability of Suppliers & Key Contractors - In a similar light to the establishment of
technology platforms, having suppliers and contractors in the same vicinity is major
advantage in many cases. As an example, the Supply Chain Group is reviewing its
sterilization capabilities and trying to establish better relationships with specific
sterilization contractors across all product sectors. The locations of these contractors in
the Asia-Pacific region may rule out certain locations due to the importance of
sterilization in the manufacturing process, assuming that the sterilization process required
for the product lines is not considered a core competency.
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- Language & Cultural Barriers - While these may not be avoided completely, it would
be advantageous to establish a manufacturing presence in a location where language and
cultural barriers will not become an issue.
2. Ability to Meet Regulatory & Government Requirements
All medical device manufacturers must work with the regulatory and government agencies of the
countries that it intends to market products in, and they should not assume that the regulations of
another agency (e.g., the U.S. FDA) supersede the local regulations. If certain agencies require
healthcare companies to have an in-country manufacturing presence, companies must evaluate the
products that they intend to sell within the country and also evaluate the operating capabilities of
that country to determine the best product manufacturing fit(s). The imposed domestic
manufacturing requirement in Russia that was discussed in Chapter 2.3 is the latest example of
this potential trend. Established manufacturing operations must also work with other government
agencies, such as those responsible for labor and environmental policy, in order to be successful.
3. Political & Environmental Stability
It is preferable to establish a manufacturing presence in locations where political and
environmental stability exist, though this may be difficult for various reasons. Simchi-Levi et al.
(2012) point to the floods in Thailand and the tsunami in Japan as examples of natural disasters in
the Asia-Pacific region that affected companies' supply chains.
4. Cost Implications at the New Location(s)
Linking with the cost and time benefits discussed in the Chapter 3.1, when evaluating what
products could be manufactured successfully in the Asia-Pacific region, various costs must be
evaluated for each location. Moreover, potential changes to and uncertainties around these costs
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should be taken into account. The following is a list of location-specific costs and uncertainties
that should be accounted for in choosing the appropriate locations in addition to being part of the
decision analysis:
- Capital Project Costs & Timelines
- Country-Specific Price Inflation
e Labor Costs & Wage Inflation
- Transportation Costs at the New Location (while it is dependent on the transportation
mode and routes for the chosen location, freight inflation will also affect this cost; further
details are discussed in Chapter 3.3)
- Changes to Foreign Exchange Rate(s) Over Time
e Import Duties & Taxes as a Result of Operating in the New Location (also evaluate
potential changes of meeting free trade agreements)
- Income Tax Strategy at the New Location
Governments may offer incentives to attract companies and industries. For instance, if a company
qualifies for Pioneer Status in Malaysia, it is exempt from paying duties on imported raw
materials if the products are manufactured for export markets (Ernst & Young, 2012, p. 7). In
addition, certain costs and uncertainties (e.g., capital project costs and transportation costs) are
dependent on how the supply chain is structured, and the next section discusses the impact of
those decisions.
The criteria above should serve as a guideline, since every medical device manufacturer will have a
different perspective on the importance of each factor. In addition, it is not necessary to evaluate every
location in the Asia-Pacific region. For the Supply Chain Group, its desire to establish a campus approach
tends to narrow the focus on certain locations versus a traditional "greenfield" approach (i.e., a new site in
a new location).
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3.3 Decision Criteria for How to Conduct Manufacturing Operations
After the products for regional sourcing are identified, the next step is to determine how supply
chain should be developed or modified and what modifications, if any, are required. Since every
manufacturer will have a different approach for developing their supply chains as part of the footprint
strategy, this section mainly provides an overview of the considerations that the Supply Chain Group has
and will face when using the methodology. Figure 8 shows the major considerations for this part of the
analysis (original figure from Christodoulou et al., 2007, p. 10):
Considerations for Outsourcing
Manufacturing Operations
IP Sensitivity
- Predictable Demand
- Low Profit Margins
- High Opportunity Cost Why?
Value Chain Analysis How?
- Firm Infrastructure & HR
Management Where?
- Procurement & Inbound
Logistics
- Operations & Technology
Development
- Outbound Logistics
Figure 8 - Decision Criteria for the "How" Analysis
The value chain analysis provides a structured way for medical device manufacturers to successfully
develop or modify their supply chains in the Asia-Pacific region while also accounting for the various
functional considerations (e.g., current procurement strategy, current transportation methods, technology
transfer experience). Porter (1985) presents a high-level overview of the value chain in Figure 9 below
(note: the model has been modified for the methodology):
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prior to making any decisions affecting internal manufacturing. The current Make-or-Buy Analysis, as
conducted by the Supply Chain Group, accounts for the following: process design / technology, supplier
quality, infrastructure requirements, impact to supply chain, and financials for both the third-party
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supplier and Company X. Once the initial decision is made, it is arbitrary as to whether products are re-
evaluated as potential outsourcing candidates. The following criteria, formed in conjunction with the
Supply Chain Group, that can be used to determine whether manufacturing for the identified products can
or should be outsourced:
1. No IP-Sensitive Information / Not Considered a Core Competency
If the technology used in the device manufacturing process is not considered part of a companys
core competency and there are no major threats to IP rights, outsourcing production should be
considered. This is especially important if there are contract manufacturers who have good
reputations for making those products while also meeting regulatory requirements.
2. Predictable Demand Forecasts
One of the difficulties with products in the early stages of their lifecycles is forecasting demand
accurately. However, if demand is relatively predictable and the forecast accuracy is high,
working with contract manufacturers should be easier since there will be less flexibility
requirements. Company X uses the mean absolute percent error (MAPE) as a way of determining
forecast accuracy. A low MAPE value is an indicator of a higher forecast accuracy.
3. Low Profit Margins
If profit margins are low, it may be feasible to find a contract manufacturer who can make the
product at a lower cost while also maintaining the same quality standards. For the Supply Chain
Group, the cost assessment is done as part of the Make-or-Buy Analysis. In addition, processes
used to manufacture devices with higher profit margins tend to require significant IP protection at
Company X.
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4. High Ooortunity Costs Compared to Other Products
In a situation where manufacturing space becomes a consideration, there could be trade-offs with
manufacturing one product versus another. For example, the Supply Chain Group is dealing with
a space issue at one of its existing facilities. In order to support production of pipeline products,
they are considering outsourcing production of products with lower production line utilization
rates and that take up a significant amount of manufacturing space in an effort to create the
required space. In this way, it could still meet customer demand while also supporting product of
newer, more innovative devices.
As mentioned before, early-stage devices that are identified as regional sourcing candidates are already
evaluated through a Make-or-Buy Analysis at Company X. However, if a product that is already produced
commercially meets the criteria listed above, the Make-or-Buy Analysis should be applied again.
Analyzing each of the components in the supply chain is an arduous task, and every medical
device company will likely have a different idea about what to investigate in developing a supply chain
for each of the evaluated products and locations. Through my research with Company X, a number of
considerations were discovered that would effect how the supply chains of all of its medical devices
would be developed. Although these considerations are company-specific, other medical device
manufacturers may face similar considerations when using the methodology. These factors, which are
grouped by their respective value chain components, are as follows:
1. Procurement & Inbound Logistics
When developing a manufacturing footprint strategy or making footprint decisions, there is an
opportunity to modify the procurement strategy of an existing product line or create a new overall
strategy. For example, local raw material suppliers could be validated and utilized in order to
increase manufacturing flexibility and decrease material lead times. In addition, there could be
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cost reduction opportunities when identifying new suppliers, but these must be reviewed in
conjunction with supplier performance. The External Operations Group would prefer to use the
suppliers that it already has established relationships with. This avoids the need for of identifying
and qualifying new suppliers, which can be very costly and time-consuming. One senior leader at
Company X believes that technologies such as injection molding and metal forming in the Asia-
Pacific region are not up to the medical-grade standards that Company X would require for its
suppliers. It would be ideal if the current suppliers had existing facilities in the region or would be
willing to expand there if the Supply Chain Group were to increase its presence there. However,
one procurement leader noted that it was not the main criterion for future success. Company X
has had experience with suppliers establishing a manufacturing location near the new locations
and not being able to deliver quality raw materials in a timely manner. If the suppliers do not
have regional locations or will not be able to establish one, the Supply Chain Group is willing to
pay to ship materials from their current locations to the new location, as long as the potential
costs (transportation, duties, etc.) and freight inflation are not significant in comparison to the
actual material costs.
2. Operations & Technology Development
The Supply Chain Group is generally conservative when it comes to transferring and modifying
unit operations or processes as part of its footprint strategy development. Although changes can
be made as part of the technology transfer process, the group tries not to make significant changes
due to the impact that the changes would have on product registrations and the ability to sell
devices in various markets. Also, if there are IP concerns with the technology transfer (e.g.,
processes with trade secrets), steps could be taken to withhold or alter those processes in order to
protect the IP. Further discussion on the topic of manufacturing intellectual property rights can be
found in Chapter 5. On the other hand, the Supply Chain Group is not opposed to outsourcing
certain operations that are not IP-sensitive and are not considered competencies. The Supply
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Chain Division at Company X conducted a process technology audit across all manufacturing
sectors over the past two years to identify its manufacturing core competencies (i.e., what
technologies were the most critical to their internal operations) and to determine what processes
could potentially be outsourced. As an example, the sterilization operations for Product Line B
could be outsourced since it is not considered a core competency (specific details can be found in
Chapter 6). Once the unit operations and processes are decided upon, the next step is to determine
what capacity is required. Although this may be dictated by the capacity needs (i.e., determined
as part of the "What" phase), there is an opportunity to include equipment and processes for
further product line growth or even for other product lines. On the other hand, it may be more
worthwhile to initially build the infrastructure and purchase equipment at a later date when the
capacity needs are better defined (as highlighted in Point 1).
3. Outbound Logistics
Outbound logistics (i.e., the type of freight used and the route) will have an impact on the supply
chain development, specifically on the lead times and the total operational costs. Company X
currently transports many of its medical devices by air freight to the distribution center(s) in the
region. While this leads to a significant reduction in lead times, it could be a significant cost
burden for most other medical device manufacturers. The Transportation Group, which is part of
the Supply Chain Group, would need to evaluate the freight type on a case-by-case basis if a new
location were to be established as part of the footprint strategy. With respect to the implications
of route preferences on Outbound Logistics, all of Company X's products sold in the region will
ship from the distribution center in Singapore to local warehouses in the countries where the
transaction(s) takes place (this is discussed further in Chapter 2.2). This has significant
implications in developing the supply chain for Product Line B as part of the case study in
Chapter 6. For example, when evaluating the Malaysia option, finished goods could be shipped
by truck from Malaysia to the distribution center in Singapore. This would be a significant cost
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advantage in comparison to the China and India options, both of which would require air
transportation to the same distribution center.
4. Finn Infrastructure & Human Resource Management
The decision to expand at an existing campus or in an existing building, in addition to planning
for capacity expansion, impacts the company's decisions around firm infrastructure and human
resource management. As mentioned before, stakeholders at Company X are primarily interested
in employing a campus approach when considering manufacturing footprint expansion as
opposed to building a single manufacturing facility in a new location. Employing a campus
approach will likely reduce the overall project costs, help develop staff capabilities around the
existing campus, and reduce operating expenses. However, the Supply Chain Group is not
opposed to considering a "greenfield" project if there are potential cost advantages that are not
available at its existing locations. In addition, an existing facility in a campus location could have
unused space that can be retrofitted for a new product line. This will lower the project
construction costs, since a new building is not required, and it will allow current employees to
develop competencies in new unit operations. The Supply Chain Group has a Site Selection
Process that helps them in identifying current sites in the network that could handle additional
capacities as needed, but a majority of the existing sites are not in the Asia-Pacific region. Once
the location(s) have been decided, the next step is to determine the current and future capacity
needs. This is a decision that the subsidiaries at Company X have had trouble with when they
managed their individual supply chain operations. On one hand, the project costs will be lower
with a "bare minimum" approach. However, building the infrastructure for future expansion early
on will reduce the costs and timelines in the future. The expansion decision must also be
coordinated with the scale of unit operations to be implemented initially as discussed in Point 3.
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Once the "What", "Where", and "How" decisions have been made, the next step is to evaluate the various
options to determine the best path forward. This evaluation involves decision analysis, and all potential
risk factors must be considered.
3.4 Decision Analysis & Accounting for the Risk Factors
When making decisions regarding the manufacturing footprint strategy, all risk factors must be
accounted for as part of the decision analysis. Table I below includes a list of the risk factors and
uncertainties, broken down by the phase in which they are most applicable, to account for as part of the
decision analysis (note: these are also discussed in the previous sections of this chapter):
Table 1 - Summary of the Risk Factors & Uncertainties to Evaluate as Part of the Decision Analysis
Methodology Phase Risk Factors & Uncertainties
* Variations in the Sales & Demand Volume Forecasts
"What' . Effect of a Supply Disruption
- Capital Project Costs & Timelines (location-specific)
* Wage Inflation
"Where" - Country-Specific Price Inflation
- Long-term Changes to Foreign Exchange Rates
- Changes to Import Duties & Taxes
* Capital Project Costs & Timelines (operations-specific)
"How"* Changes to Material Costs
Freight Inflation (combination of price changes to fuel & freight)
Since there are many uncertainties and risks to observe, the most effective way to account for them is to
develop three distinct scenarios - optimistic (best-case), realistic, and pessimistic (worst-case) - for which
the decision analysis tools can be applied. The uncertainties and risk factors are considered to be more
favorable in the optimistic case and vice-versa for the pessimistic case. Appendix A illustrates how these
risks factors and uncertainties were accounted for in the case study for Product Line B, and Table 11 in
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the appendix lists the values that were applied. These values were determined through a combination of
economic outlooks, industry research, and input from key experts across Company X.
Three decision analysis tools can be used to determine the best way forward with regards to
footprint strategy. Each of the tools selected provides certain information that the other tools do not, and
using them in combination can provide a complete picture. The following tools, along with the reasoning
for their respective selections, were used for the evaluation in Chapter 6:
1. Total Landed Cost Analysis
Calculating the total landed costs can help to determine which of the locations chosen will be able
to supply the Asia-Pacific region at the lowest cost, and they can be compared against the total
landed costs for the current source. For Company X, the total landed cost analysis includes
specific costs that are generally accounted for in the NPV analysis conducted by the Finance
Group, thus providing a way to determine the impact of those elements. Simchi-Levi et al. (2008)
give an overview of the components that should be accounted for in a landed cost analysis (p.
288). The analysis should be conducted for each of the three scenarios to determine the variation
in landed cost.
2. Net Present Value (NPV) Analysis
Simply put, this is used to determine the value of a potential investment for each scenario. The
total landed cost analysis does not fully account for the initial investment requirements for each
project, and an option that has a lower total landed cost over the scenarios analyzed may not be
the most prudent investment when accounting for the capital project costs. Moreover, the results
of the NPV analysis for each of the three scenarios are needed for the decision tree analysis as
discussed in Point 3. Medical device companies will have slight variations on how the NPV is
calculated based on their preferences. At Company X, the Finance Group is working towards
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standardizing the way that the NPV analyses are conducted across the entire organization. The
NPV analysis conducted in this evaluation was completed with the company's existing model,
and specific model details cannot be provided in order to protect proprietary information. Similar
to the total landed cost analysis, the NPV should be calculated for each of the three scenarios to
determine the variation between the values.
3. Decision Tree Analysis
A decision tree can be used to determine the best decision to make under scenarios that take into
consideration various uncertainties and risks. As part of the manufacturing footprint strategy
development for Company X, this analysis can be used to determine if it would be worthwhile to
expand manufacturing operations in a new regional location or continue manufacturing in an
existing location. In situations where the total landed cost and NPV analyses tend to favor a
single sourcing option (e.g., due to an existing location with sunk costs or perhaps because of the
investment requirements), a decision tree analysis can account for the possibility of a plant-wide
failure to determine whether it is more valuable to use a single or dual sourcing strategy. For this
analysis, the NPV values for all three scenarios are required inputs for the decision tree analysis.
The overall results for the analysis conducted with Company X are given in Chapter 6, and further details
can also be found in Appendices A and B. The original data for the total landed cost and NPV analyses
presented in Chapter 6 and Appendix B was modified to protect confidential information for Company X.
It is also worthwhile to conduct some type of sensitivity analysis to determine how the outcome
will change as the uncertainties change. The results from the sensitivity analysis can be used as "trigger
points" to determine when a new plan of action is needed. Chapter 6 also includes the results from the
sensitivity analysis performed that can aid in determining what factors have the greatest influence on the
decision.
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4 A Business Process for Making Footprint Strategy Decisions
There are a number of ways that the methodology described in Chapter 3 can be applied in order
to make footprint strategy decisions. Company X is concerned with who should be involved, what data
should be reviewed, and how often should a review be completed. Experts at the Institute for
Manufacturing at the University of Cambridge believe that the business process "needs to be fully
integrated into the business planning cycle and needs to be the definitive basis for all manufacturing
network decisions" (Christodoulou et al., 2007, p 40). This chapter explores a business process for
making manufacturing footprint strategy decisions and outlines a process designed for Company X.
4.1 Roles & Responsibilities
The objective for each team member is to develop and share the information required per the
outlined methodology, and the team must develop consensus around the shared results. In developing an
Asia-Pacific manufacturing footprint strategy, input from the following groups is needed as part of the
business process:
- Manufacturing Operations & Strategy
e Engineering
- Quality & Regulatory Affairs
- Commercial Operations (i.e., sales & marketing)
- Research & Development
- Production / Demand Planning
- Procurement & Strategic Sourcing
- Logistics (i.e., transportation, distribution)
- Finance
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* Human Resources (HR)
Although having enough representation from various groups is required in order to gather data quickly
and make an informed decision, having too many people involved can make it difficult to build consensus
within a suitable timeframe. Certain individuals can provide input from multiple groups based on their
role in the company and/or previous experience. In addition, there should be a designated leader to
coordinate responsibilities as part of the business process.
Six roles were identified as being crucial to the business process at Company X, and one person
should represent each group. Table 2 shows the members of the primary team and their roles in the
business process, including what information they are responsible for (note: team members from the
Subsidiary Operations Development and Finance Groups are not directly part of the Supply Chain
Division even though they work closely with the division in general):
Table 2 - Roles and Responsibilities for Each Member of the Business Process at Company X
Group Business Process Role & Primary Methodology Inputs
Represented Responsibilities ("What", "Where", "How")
- Team lead Coordinating with HR: Talent
- Responsible for providing input Availability, Language & Cultural
from the following groups as part of Barriers, Political & Environmental
the process: HR, Legal Affairs, and Stability, and Human Resource
Transportation Management
e Coordinates with Manufacturing Coordinating with Legal Affairs: IP
Supply Chain and Finance on their required issues
Strate deliverables as described in their e Coordinating with Transportation:
respective sections Requirements for Inbound and
Outbound Logistics, Associated Cost
Implications and Potential Benefits
(e.g., decreased lead times, cost
savings)
Decision Analysis and Risk Factors
- Represents the Commercial and - Regional and Global Demand
Subsidiary R&D Groups as part of the business - Process Complexity (e.g., regulatory
Operations process classification, process maturity, IP
Development Provides data for the expected sales issues, operating capabilities
forecasts required, investment required)
e Coordinates with all other team e Requirements for Firm Infrastructure
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members to provide support as
needed based on his/her in-depth
product operations experience
and Operations/Technology
Development
- Provides demand volume forecasts e Current Network Capacity (and
and capacity utilization future needs)
" Coordinates with External * Coordinating with External
Operations on procurement Operations: Procurement
Manufacturing requirements Requirements, Supplier Availability,
and Proximity to Suppliers
- Requirements for Firm Infrastructure
and Operations/Technology
Development
e Provides input for capital project - Investment Required (e.g., capital
requirements, manufacturing project costs)
process technologies, and validation - Operating Capabilities and IP
requirements Requirements (e.g., core competency
Manufacturing determination)
Engineering * Technology Availability (bylocation)
* Requirements for Firm Infrastructure
and Operations/Technology
Development
* Provides input on quality - Process Complexity (e.g., regulatory
considerations for the processes classification, process maturity, IP
being evaluated (e.g., process issues, operating capabilities
maturity, quality requirements for required, investment required)
raw material & finished goods) - Ability to Meet Government and
Quality e Provides input for regulatory and Regulatory Requirements
product registration requirements - Requirements for Firm Infrastructure
for each potential location and Operations/Technology
Development
e Provides financial input to the team - Operating Costs (current and future)
(e.g., cost accounting, tax strategy, e Investment Required
Finance economic risk factors) e Decision Analysis and Risk Factors
- Coordinates with Supply Chain
Strategy on completing the decision
analyses
The Supply Chain Strategy Group, which is a separate group within Company X's Supply Chain
Division, includes members who work specifically in the medical device sector. The personnel in the
group are the most suited to lead the business process due to their previous experience with
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manufacturing strategy projects and existing relationships with supporting groups. If additional people are
required to provide input as part of the process, the team can be expanded. However, the group size
should not grow beyond ten persons in an effort to efficiently build consensus. The initial team will run
through the methodology criteria described in Chapter 3 and evaluate the decided-upon possibilities as
part of the decision analyses. Although each role has specific inputs that they are responsible for, these
can be shifted if certain members are better suited for providing the required inputs (e.g., a member from
the Subsidiary Operations Development Group could provide the required procurement information if he
or she has previous experience in this field). It is up to the team leader to decide. The team will report the
results and any required information to the leadership team for the Supply Chain Group.
The Supply Chain Strategy Group will also be responsible for analyzing the updated information
periodically as part of the business process. If any changes occur that require changes to the
manufacturing footprint for the product lines identified, the person responsible should contact the
Subsidiary Operations Development Group to verify these changes and discuss next steps. Both parties
work closely together in the project formation and execution phases at Company X currently. If a formal
project is required, the responsible person(s) will approach the senior leadership team in order to initiate a
capital approval request.
4.2 Frequency of the Review Process
The timeliness of the decision-making process is another key concern. Christodoulou et al. (2007)
found that the decision-making for a manufacturing footprint strategy is usually completed on an ad-hoc
and infrequent basis, and it is usually done in response to profit loss or increased competition. The
information gained from the initial analysis should be reviewed frequently to keep track of any changes
that may happen. For Company X, the information should be reviewed quarterly or semi-annually,
depending on how often the revised data is available. This will allow enough time for the Supply Chain
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Group to proactively react to potential changes instead of finding out about them after the fact. For
example, Company X may not be able to react quickly enough to a major regulatory change (e.g.,
implementation of Pharma 2020 in Russia) if the data were only reviewed annually. If any changes are
identified that warrant modifications to the manufacturing network as decided by the team (e.g.,
significant increases to the sales forecast or major changes to import duties), the Supply Chain Strategy
should work together with other supporting groups (e.g., Subsidiary Operations Development, Finance) to
evaluate the project using the current project assessment tools available. Furthermore, the leadership team
of the Supply Chain Group can prioritize potential projects as part of annual planning cycle or sooner if
required.
The Supply Chain Group has already developed a Network Strategy Toolkit, which includes
actionable steps taken during a project's development, deployment, and implementation. The existing
toolkit does not follow a rigorous process for using the decision analysis tools, and both the team
formation and the analysis is done on a case-by-case basis. The business process presented in this chapter
provides a structured way for manufacturers to organize and manage the process, and these elements
should be integrated into the toolkit developed by the group.
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5 Intellectual Property Considerations for Footprint Strategy Decisions
When developing a manufacturing footprint strategy, intellectual property (IP) rights must be
considered when evaluating a potential manufacturing location. One of the most concerning issues when
considering manufacturing footprint strategy development for the Asia-Pacific region is trade secret
protection. Although most countries in the region have laws to protect IP rights, certain countries, such as
China, are still known for counterfeiting and their lack of IP protection (Bai and Da, 2011). While other
forms of protection, such as patents and copyrights, are legally protected for a finite amount of time, trade
secrets are only protected as long as they are safeguarded. Thus, if a trade secret is revealed to a
competitor in any way, it can be very difficult to make up for the financial loss and brand damage.
In this section, the properties of a trade secret are explained, and an example is provided to
demonstrate how the properties can be applied to the Process Technology A at Company X. In addition,
the ways to protect trade secrets are described in further detail. The investigation conducted has led to an
overall understanding that manufacturing processes that involve trade secrets should generally be located
in countries with strong reputations for IP protection.
5.1 Trade Secret Definition & Requirements
Many sources define what a trade secret is and what constitutes a trade secret. One of the most
widely accepted definitions of a trade secret comes from the Unified Trade Secrets Act, which defines a
trade secret as "'information, including a formula, pattern, compilation, program, device, method,
technique, or process, that (i) derives independent economic value, actual or potential, from not being
generally known to, and not being readily ascertainable by proper means by, other persons who can obtain
economic value from its disclosure or use, and (ii) is the subject of efforts that are reasonable under the
circumstances to maintain its secrecy" (National Conference of Commissioners on Uniform State Laws,
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1985). Examples of famous trade secrets include the recipe for Coca-Cola@ and the formula for WD-
40@.
In order for a process to be considered a trade secret, Jorda (2007) and Dratler (1991) argue that
the following criteria must be met:
1. The process gives the manufacturer a competitive advantage over the competition
The process provides either a cost advantage or a product characteristic advantage. For example,
a manufacturing process that allows a company to minimize its operating costs will give it a
competitive advantage and could be considered a trade secret.
2. The process itself is kept a secret
Pertinent information is safeguarded from the public and personnel that are not involved in the
operations. Protection can include keeping documents under lock-and-key or having password
protection with digital documents. In certain cases, certain setup or operating steps may only be
known by certain individuals to mitigate the release of proprietary information.
3. The process is not generally known or used by competitors (i.e., not common knowledge)
If a process is well known among competitors, it cannot be considered a trade secret. However, it
is possible for a trade secret to be known and used by other competitors, as long as they
developed the processes independently (Jorda, 2007).
If a manufacturer were to file a lawsuit against another party for trade secret misappropriation, this
criterion would need to be satisfied in the eyes of the court. Assuming that all three points are met,
manufacturers must then decide what steps to take in order to protect it.
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5.2 Trade Secret Protection Methods
Based on the research conducted, there are three ways that a company can protect its trade secrets
when looking to expand its manufacturing footprint:
1. Ensure that it is illegal for employees with process knowledge to reveal proprietary information
and reminding those individuals of their legal obligations
2. Utilize other IP protection methods in combination with trade secret protection
3. Use a different process to produce a component or device in order to protect the original trade
secret process
Company X currently employs the first and second ways to protect its devices that are currently available.
Both the Supply Chain Group and product experts in each of the subsidiaries manage IP protection for the
range of devices. The benefits and risks of each way are examined in the upcoming sections.
5.2.1 Applying Current Legal Methods to Ensure Protection
There are many ways to protect a trade secret from the outset. One of the most common ways is
to have individuals who are potentially exposed to such proprietary information sign a number of
confidentiality agreements, including but not limited to the following agreements: non-disclosure, IP
assignment, and non-compete. Jorda (2007) suggests other ways to protect proprietary information, such
as conducting regular training and exit interviews for people exposed to proprietary information in order
to remind them of their obligations. In addition, manufacturers should continue to protect information
relating to process trade secrets by any means possible so as to avoid the information from falling into the
wrong hands.
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While these methods are certainly applicable, there is still the risk of an employee breaking the
law and revealing the trade secret(s) to other companies or using them for personal gain. China and India
both received poor rankings for intellectual property protection in a 2012 survey conducted by the Global
Intellectual Property Center of the U.S. Chamber of Commerce, signaling weak IP protection in both
countries; in fact, both countries received the lowest scores for trade secret protection (Global Intellectual
Property Center, 2012). Manufacturers should keep this in mind when developing their footprint
strategies.
5.2.2 Combining IP Protection Methods to Protect a Trade Secret
In addition to adhering to the traditional methods of protecting a trade secret, further protection
can be done by utilizing other forms for protection, such as patent protection, copyrights, and trademarks.
For example, Dratler (1991) recommends copyrighting the instructions for a specific process so that
competitors cannot use the exact same document. Another example, which is currently employed by
Company X and many of its competitors, is to patent parts of the product design. The respective
subsidiary in Company X has several patents for Product Line B that include information specific to the
design of the instrument and the consumable component.
Although patents and copyrights serve as additional steps for protection in these circumstances,
there is no legal protection on the design or instructions once the patents or the copyrights expire.
Competitors are free to copy and sell the products at will. In a similar light, medical manufacturers should
be very careful when patenting a manufacturing process outright; competitors are allowed to use the
process once the patent has expired. Moreover, certain competitors will not be dissuaded by additional IP
protection in the Asia-Pacific region as evidenced by Bai and Da (2011).
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5.2.3 Using a New Process to Manufacture the Intended Product
The most effective way to protect a process containing a trade secret is to change the process in
such a way that the trade secret is not applied outright (i.e., reinvent or modify the process). Such a
change would require significant process development expertise and time in order to execute.
Furthermore, there is a high probability that the new process will be less efficient than the trade secret
process, so this should be considered when evaluating the required manufacturing output at a facility.
This scenario should only be considered if a medical device manufacturer is willing to sacrifice an
operational advantage in order to gain or increase market access (e.g., the requirement to manufacture
50% of products domestically in Russia).
While this may be enticing for companies that must produce in a location that does not maintain
adequate IP protection, there are significant risks. First, if the product manufactured is intended for export
to other countries, changes to the product registration will be required in order to distribute products that
are manufactured using the new process. The product registration process requires manufacturing process
validation for the products and components sold in that country. Second, since a new process is being
used to make the same product, the government health agency in the country where re-registration is
occurring could require additional steps to verify that the product manufactured through the new process
performs to the same expectations to those manufactured in the old, trade secret process. This could
require additional clinical trials, directly adding additional costs and lengthening the time requirements
for product registration. Based on these risks, process modifications should only be made in extreme
circumstances. Two examples include the following: if the products manufactured using the modified
process will only be sold in a country requiring the new process, or if the manufacturer believes that costs
for the changes to product registration and the required trials are not significant compared to the potential
revenue gain.
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5.3 A Case Study with Process Technology A
Product Line B, which was evaluated as part of the case study in Chapter 6, includes two
components needed to perform its intended use during a procedure - an instrument and a consumable
component. The revenue from the consumable component made up nearly 65% of revenues for Product
Line B in 2011. Company X has developed a robust process technology (Process Technology A) to
assemble these components at a rapid pace and with minimal operator intervention. The process efficiency
has allowed the franchise to significantly minimize production costs, and the consumable components have
higher profit margins than the instruments themselves. If competitors were able to produce the same
components, Company X would lose significant market share and revenue. Moreover, there could be
product safety issues if the competitors did not produce them to the same quality standards. In many ways,
the associated recalls could be more detrimental to Company X than the actual revenue loss.
There has been some debate at Company X as to whether Process Technology A should be
considered a trade secret. Based on the criteria defined in Chapter 5.1 the process should be considered a
trade secret as described in Table 3 below (Jorda, 2007; Dratler, 2001):
Table 3 - Evaluation of Process Technology A as a Trade Secret
Trade Secret Criteria Reasoning for Process Technology A
- Process Technology A allows for to mass-production the assembled
Process Provides a consumable components with minimal operator intervention (i.e.,
Competitive Advantage low-cost operation).
- Machine and process drawings for the process are password-
protected.
Process is Kept Secret - The setup procedures are only known by certain Maintenance &
Engineering staff, and extensive training is required
- A minimal number of competitors make the consumable components
comparable to those for Product Line B.
Process is Not Common - Counterfeit components have not been found in distribution channels
Knowledge (note: counterfeit instruments have been found though) according to
Company X.
57
The Supply Chain Group has taken a number of precautionary steps to protect Process Technology A.
Employees at the facilities where the technology exists must sign a non-disclosure agreement that
includes a non-compete clause. Exit interviews do generally take place to remind employees of their legal
obligations after they have left the company. As mentioned in Chapter 5.2.2, the group has also patented
its component design in conjunction with patents pertaining to the instruments. Therefore, if a competitor
or a counterfeiter were able to use the same process, they would need to design a new consumable
component that could be used by the same instrument. This, in itself, is a daunting task with no
guaranteed success.
Certain personnel who are familiar with Process Technology A have found a potential way to
modify the process in such a way as to protect the proprietary knowledge of the original process. The
change involves loading the components into the machine so that certain elements of the original machine
design would not be needed in the new process. While further development is required, there are
immediate issues with this change. First, it will take an immense amount of time and resources to develop
and implement the new process. In addition, assuming that the modified process is not as robust as the
original process, a greater investment would be required in order to match the expected output that the
original process could deliver. Second, there would be modifications to current product registrations, and
new clinical trials may be required in order to sell the new components. These are major hurdles for the
Supply Chain Group, so much so that certain Group leaders are willing to locate the process as is in
countries such as India and China rather than modify the process for further protection.
5.4 Valuing the Loss of a Trade Secret
As mentioned before, Company X is hesitant to place certain process technologies in places such
as China and India for fear of trade secret misappropriation. In addition to the loss of the trade secret
itself, the company would have to prove in the respective courts that trade secret misappropriation
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actually took place. This can be challenging in situations where Company X had limited legal experience
in a certain country or if that country does not have stringent laws around intellectual property. Bai and
Da (2011) review a variety of trade secret misappropriation cases that took place in China. Although trade
secret enforcement is possible, the burden of evidence is higher for the plaintiff (i.e., the group or
company that lost the trade secret) compared to what is required in the United States (Bai and Da, 2011).
A process technology can be used to produce either a competitive product (i.e., the competitor is
not found guilty of trade secret misappropriation and competes directly with the existing producer) or a
counterfeit product that appears and functions like the original product. Groups or companies making
counterfeit products will not have to pay the marketing costs associated with a competitive product, since
they are attempting to penetrate the current manufacturer's supply chain rather than compete against
them. However, since their product is a counterfeit, they could be subjected to further violations of
intellectual property rights beyond trade secret misappropriation (e.g., copyright and trademark laws). For
Product Line B, Company X has found counterfeit versions of the instruments, but it has not found
counterfeit versions of the consumable components in the Asia-Pacific region. Since very few companies
make competitive products with Product Line B, Company X believes that those who are able to ascertain
information about Process Technology A will be able to produce the consumable components and make
either counterfeit or competitive products.
The true value of a trade secret loss will depend on the product (competitive or counterfeit) and
the circumstances. For instance, the costs and customer acceptance rates would be different in the
situation where the trade secret were used to manufacture counterfeit products compared to a situation
where the trade secret was used to manufacture a competitive product. Through the research conducted
with Company X, a generic equation to determine the economic value of a trade secret if it were revealed
was determined as follows:
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Trade Secret Value
- (Global Net Profit x Global Market Penetration x Customer Acceptance) + Remedy Costs
Global Net Profit represents the total net profit that is tied to the process technology. The global
net profit tied to Process Technology A, which is an essential process step in making the consumable
component, is more than three quarters of the global net profit for Product Line B. Company X
conservatively assumes the highest value for Global Net Profit that accounts for all of the product lines
utilizing the trade secret process. However, the competitor or counterfeiter may not understand the full
implications of the trade secret and, therefore, not maximize the economic value (e.g., competitors not
producing other products that utilize the trade secret).
Global Market Penetration represents the percentage of the market that is affected by the trade
secret misappropriation. For counterfeit products, global market penetration will be higher if those
products are found in multiple regions worldwide. The Supply Chain Strategy Group assumes a 100%
market penetration value in those situations. Company X also reported that it has found competitive and
counterfeit products that were only sold in a few specific countries are not found to be circulating in its
international supply chain. The market penetration would be lower in those situations since only a certain
location or region is affected.
Customer Acceptance represents the probability that customers will buy and use the other product
over the other product. If it is a counterfeit product that the customer purchases unknowingly, the
probability of customer acceptance is typically low. Company X has extensive procedures for what
customers should do if they have been unknowingly sold a counterfeit product. On the other hand, if the
new product is considered to be a competitive product, the customer acceptance value could be higher.
For Product Line B, Customer Acceptance will be higher if the competitor is able to sell the consumable
components at a much lower cost, assuming that it is a competitive product. However, it will likely not
reach 100% due to brand loyalty by customers or the competitive discounts that Company X would need
to offer.
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Remedy Costs represent the costs required for these will be different under each circumstance.
For example, if counterfeit products were manufactured using the trade secret and it is deemed as a trade
secret misappropriation, the costs will include all associated legal fees and costs for product recalls
needed in order to determine the impact the supply chain. While the total cost of the recall will vary by
the situation and the industry, companies estimate the recall costs to be $30M or less (Ernst & Young,
2011). However, the costs could increase significantly if patients are harmed through the use of a
counterfeit product. If the trade secret is lost but the court does not rule it as trade secret misappropriation,
the costs will include the additional marketing costs needed to stay competitive as well as the associated
legal fees. In addition, the company will likely have to reduce its prices to stay competitive in the affected
markets.
There are limitations with the equation that will also vary on a case-by-case basis. First, these
costs do not reflect the potential damage to a company's brand reputation, especially if a product recall is
required in the case of counterfeit products (Ernst & Young, 2011). Second, the values for Global Net
Profit, Market Penetration, and Customer Acceptance could change over time if the competitor is not
guilty of trade secret misappropriation and is able to successfully compete in the market. Company X is
trying to gain a better understanding of these changes with its Asia-Pacific competitors. In this case, the
equation still provides a starting point for the total economic loss due to trade secret misappropriation.
5.5 A Potential Path Forward with IP Protection in the Asia-Pacific Region
While the relevant IP protection mechanisms are in place, there may be competitors who will still
ignore the legal implications and attempt to copy these devices or processes. If the Supply Chain Group
were to locate manufacturing for Product Line B in places such as China or India, it would be taking a
risk by including Process Technology A as part of the process operations. On the other hand, the Global
Intellectual Property Center Report commented that Malaysia, which is also evaluated as a potential
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location in Chapter 6, has "reasonable trade secret protection" due to key rulings in recent court cases
(Global Intellectual Property Center, 2011, p. 60). It may be possible to only manufacture the instruments
at the new facility but then they would need to continue shipping the consumable components from the
current facility in North America. A certain number of these components would also need to be shipped to
the new regional manufacturing location in order to test the instrument as part of the manufacturing
process. The Supply Chain Group would prefer to have the instrument and component manufacturing
processes in the same location.
Given the risk of counterfeiting in the region and the risks of implementing a new process to
make the same product, it is advisable to locate manufacturing processes with trade secrets in locations
with strong reputations for IP protection. Examples in the Asia-Pacific region that are known to have such
a reputation include Japan, Singapore, and Australia. However, these locations are also known to having
higher operating costs, so the potential savings may not be as great when compared to manufacturing in
the U.S. or Western Europe. For the purposes of the case study in Chapter 6, it was assumed that IP
protection for Process Technology A could be established in all three with no process modifications
required. In reality, this decision would need to be reviewed further by the business process team as
outlined in Chapter 4.
62
6 Application of the Methodology at Company X
This chapter presents a case study using the broadly applicable methodology that I developed as
part of my research with Company X. The methodology is applied to a subsidiary within the company
that develops and markets a variety of medical devices. This subsidiary was initially chosen for its Asia-
Pacific growth opportunities over the next seven years and the fact that the product lines are currently
single-sourced (i.e., only one manufacturing location).
The decision analysis tools were applied to three specific regional options, and each location had
a different manufacturing setup with different space constraints, project costs, and operating costs. The
Malaysia option is a "greenfield" project; the China option includes a new manufacturing facility on an
existing campus; and the India option is a retrofit of a vacant and available space within an existing
facility. These options were compared to the current source in North America. At the time of writing, no
engineering modifications (e.g., a facility expansion or additional assembly equipment) would be required
to meet the expected future demand in North America till 2019. Additional labor shifts, although costly,
could be added to meet demand if the circumstances required such action. Thus, the decision analysis
needed to show that the benefits derived from expanding in any of the Asia-Pacific locations chosen
outweigh the costs in the existing North American location, where the infrastructure already exists (i.e.,
there are sunk costs). In this case study, we find that those benefits do not justify expanding in the Asia-
Pacific region. However, project leaders in the Supply Chain Strategy Group acknowledge that there may
be situations with other subsidiaries in which the regional expansion benefits outweigh the expected costs.
Although the methodology was applied to a subsidiary with existing product lines and with some
existing capacity, it is also applicable for product lines that are not currently being manufactured since the
user would follow the same steps in order to determine the best course of action with regards to expansion
decisions (e.g., deciding whether it is better to build a new facility at an Asia-Pacific location or to build
commercial manufacturing capabilities in another location). This situation is discussed in more detail in
Chapter 7.1. The data presented in this chapter has been modified to maintain the confidentiality of
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Company X's proprietary information where it was deemed appropriate. Appendices A and B include
detailed information regarding the analysis.
6.1 Evaluating What Products are Suitable for Regional Sourcing
Chapter 3.1 outlines the criteria needed to determine what products make sense for regional
sourcing for the chosen subsidiary. This subsidiary accounted for nearly 8% of Company X's total
revenue in 2011. Product Line B was chosen as a suitable candidate for regional sourcing compared to
other product lines primarily because of the anticipated demand growth in the Asia-Pacific region and
worldwide as well as the potential capacity limitations beyond 2017. Certain issues were identified when
evaluating the process complexity and the financial implications of expanding the manufacturing
operations in the Asia-Pacific region. However, the Supply Chain Strategy Group believed that it was
worthwhile to continue the evaluation based on the potential benefits of having another manufacturing
location besides North America. Following the methodology, the first step is to review the sales forecasts
that are available at Company X.
Regional & Global Demand
To understand the regional demand, sales forecasts were obtained and reviewed with the guidance
of the subsidiary's Commercial and Finance Groups. Figure 10 shows the expected sales growth for
various product lines in the Asia-Pacific region (note: the product lines have been designated with
alphabetical letters, and the scale for the revenue has been removed to maintain the confidentiality of
proprietary information for Company X):
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Figure 10 - Expected Product Line Growth in the Asia-Pacific Region for the Subsidiary
We can see that Product Lines B, D, and F have the highest growth rates. Product Lines B, F, and H are
expected to be the top revenue drivers for the subsidiary in the region by 2019. These results were
compared against the global revenue forecasts shown in Figure 11 below (note: once again, the scale for
the revenue has been removed to maintain confidentiality of proprietary information for Company X):
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Figure 11 - Expected Product Line Growth Worldwide for the Subsidiary
In this case, we see that the global growth rates are generally not as high as the regional growth rates.
However, there is a strong correlation between the regional growth rates and the global growth rates for
the product lines evaluated (r = 0.981), signifying that a products with high global growth rates will likely
have high regional growth rates and vice-versa.
Of the products lines evaluated, Product Lines C and H have market-appropriate products that are
currently being sold or developed. However, a contract manufacturer is currently manufacturing those
products, and the External Operations Group confirmed that it is unlikely that manufacturing for these
products would be brought back in-house. Similarly, manufacturing operations for Product Lines G and I
are also outsourced to a contract manufacturer, but there is less incentive to manufacture those products
internally due to low projected revenues versus the costs required to manufacture them in-house.
Therefore, the opportunity for the Supply Chain Group to manufacture those products (market-
appropriate products for Product Lines C and H as well as all products for Product Lines G and I) in the
region is minimal at this time. There is still the potential opportunity to manufacture other product models
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for Product Lines C and H. However, after evaluating the current network capacity, which is explained in
the upcoming section, the need for additional capacity to meet future demand for those product lines does
not currently exist.
Current Network Capacity
Figures 12 and 13 show the expected capacity utilization rates for each manufacturing production
line based on the modified global demand volume forecasts in the optimistic scenario. This data was
created and is maintained by the Manufacturing Group within the Supply Chain Group. These rates do not
take into consideration capacity for the packaging and sterilization operations. However, the
Manufacturing Group confirmed that the required capacity for those operations would be available over
the five-year horizon (i.e., less than 80% utilization over that timeframe).
The capacity utilization rates show the percentage of time that the production lines will need to be
operated in order to meet global demand, assuming with no major operational delays. The total amount of
time available for each manufacturing line is 80 hours per week (the plant normally operates 16 hours per
day from Monday through Friday). Any time above 80 hours per week is considered overtime at that
location. The Manufacturing Group within the Supply Chain Group strives to keep the capacity utilization
rates of between 30% and 80% (green). Below 30% (yellow) is a clear indication of excess capacity for
the manufacturing line. Utilization between 80% and 100% (blue) is an indication that the capacity will
become limited if demand continues to grow and no process improvements are made. When capacity is
above 100% (red), it means that additional shifts will be required to meet demand.
Based on this information reviewed, certain stock-keeping units (SKUs) for Product Line B could
potentially face capacity constraints within the five-year horizon more so than other product lines. This
means that unless steps are taken to increase productivity or output within the next four to five years and
depending on forecast accuracy, there is a chance that customer demand will not be met. The current
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operations in North America will be able to support the global demand for the other product lines even
with no changes to work scheduled (i.e., not going beyond 80 hours per week).
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Figure 12 - Capacity Utilization for the Manufacturing Lines Associated with Product Lines A - E
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Figure 13 - Capacity Utilization for the Manufacturing Lines Associated with Product Lines F - I
Process Complexity
The evaluation of process complexity provided key insights into the various product lines for the
subsidiary. Overall, there were concerns regarding the IP rights and the locations of current suppliers for
the product lines. However, since the potential investment costs and the required operating capabilities
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would not be significant compared to those required for other subsidiaries at Company X, the potential
benefits of having another manufacturing location could potentially outweigh these risks for certain
product lines. Table 4 presents the observations that were made during the implementation of this part of
the methodology:
Table 4 - Process Complexity Assessment for the Subsidiary
Cost & Time Benefits
Through the evaluation of the current costs and lead times for products shipped to the Asia-
Pacific region, we find that the financial benefits for expanding in the region are somewhat limited
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Evaluation Criteria Key Observations
e All product lines are FDA Class II devices, meaning that
Regulatory Classification registration requirements are relatively straightforward in theAsia-Pacific region except in China).
* Only Process Technology A (described in Chapter 5) requires
stronger IP protection versus the other process technologies and
unit operations required. As mentioned in Chapter, certain
IP Rights leaders at Company X would consider placing this technology
in the region with the assumption that the sites could handle the
IP protection requirements.
e Process maturity is variable at the SKU level for most of the
product lines.
- Product Line H is generally considered to be the most mature
Process Maturity (later stages of their product lifecycles).
* Product Line D is generally considered the least mature (newest
product line).
e No major internal capabilities are required compared to the
Operating Capabilities operational requirements for the other medical device
Required subsidiaries at Company X.
- The investment in equipment and building construction would
Investment Required be significant when compared the requirements of the other
medical device subsidiaries at Company X.
besides the ability to reduce logistics costs by meeting free trade agreements within the region. Table 5
highlights the observations made:
Table 5 - Cost & Time Benefits Assessment for the Subsidiary
Potential Benefits Key Observations
Lead Time e Since all finished goods are shipped to the regional distribution
center by air, the change in lead times would only be a few days.
This also assumes no interruptions or delays in raw material
supply.
Proximity to Suppliers - A majority of current suppliers are based and manufacture
materials in North America. Developing the local supplier
capabilities in the Asia-Pacific region would require significant
resources (cost and time).
Operating Costs - Since the current North American operation already utilizes a
location with low labor and utility costs, there will not likely be a
significant decrease in these costs when compared to a new
location in the Asia-Pacific- region.
- Across all product lines, labor costs (direct and indirect) account
for less than 5% of the production costs. This is significantly lower
than the labor cost percentage for other medical devices at
Company X.
Logistics Costs e Although the finished goods shipping costs from a new Asia-
Pacific location to the regional distribution center will be less, the
raw material shipping costs will likely be higher since a significant
percentage of products will continue to be shipped from North
America (the exact percentage varies for each scenario in the
decision analysis).
- Due to the current North American location, Company X is not
able to take advantage of certain free trade agreements that are
available in certain countries within the Asia-Pacific region. This
would allow the company to pay lower rates for import duties and
taxes. In order to meet these agreements, however, the External
Operations Group must meet specific procurement requirements
(e.g., it must source at least 65% of raw materials from the Asia-
Pacific region), which vary for each country.
Tax Strategy - For all of the products lines evaluated, the income tax rates are not
likely to change. Further details cannot be revealed in order to
maintain confidentiality.
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Selecting the Product Line(s)
Once all of the data was gathered, members of the Supply Chain Strategy Group reviewed it to
gain a better overall picture. Based on the information derived as part of this case study, Product Line B
was identified as a candidate for regional sourcing. In addition to being a key growth driver in the region
and worldwide, it will be the first product line for the subsidiary to face capacity constraints with the
existing North American operations. The primary risks identified in this evaluation were the IP rights
with Process Technology A and the development of a robust procurement strategy given the distance
from current supplier locations. However, due to the expected demand and potential capacity restrictions
over time, it was determined to be the most suitable candidate at this time.
6.2 Evaluating Where the Products Should Be Manufactured
In this phase of the methodology, five locations were selected for further analysis using the
framework discussed in Chapter 3.2. Since the Supply Chain Group already has manufacturing operations
in China and India, selecting a site in each country was warranted in order to align with the preferred
campus approach and because of the proximity to the end-users of the devices. Locations in Malaysia,
Thailand, and Singapore were also considered as part of this analysis. Thailand was eliminated from
consideration due to environmental stability issues (e.g., flooding), minimal operational capabilities
currently in existence, weak IP protection, and potential language barriers. In addition, Singapore was
eliminated based on the high operating costs compared to the other locations. At this time, no countries in
the Asia-Pacific region explicitly require domestic production of medical devices in order to sell products
in that country. Countries with such regulations would have been included in this part of the analysis if
this had been the case. Tables 6 and 7 show the benefits and risks for each of the locations that were
considered as follows:
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Table 6 - Benefits & Risks for the Malaysia & China Locations
I Operatin Capabilties
*Another group within the
division has a manufacturing
presence
*Current suppliers with
manufacturing locations
(sterilization and plastics
primarily)
*"Up-and-coming" location
for the medical device
industry
*Minimal cultural issues
*No existing presence for
the Supply Chain Group
*Existing presence for the
Supply Chain Group
*Current suppliers with
manufacturing locations
Ability to Meet Regulatory
& Government
Requirements,
*No major issues identified
for the specific location
*Company X has developed
relationships with the local
agencies with its previous
experience in the area
romechanical primarily)1
*Weak IP protection
*Only one contract sterilizer
identified
*Cultural issues identified
(employee turnover,
language barrier, etc.)
*Additional clinical trials
required to sell products
domestically (-1 year delay)
Political & Envimnmental
Stability
*Government has strong
support (i.e., political
stability)
*No major environmental
issues identified
*Minor ethnic tensions in
the past
Cost Imiucations
*Government incentives
(e.g., exempt from raw
material import duties, aid in
construction costs)
*Low operating costs (labor,
overhead)
*Proximity to the regional
distribution center in
Singapore
*Expected currency
appreciation
*High setup costs (capital
proje9ct)
*No major issues identified *Leverage infrastructure at
for the specific location |the existing site
*ligh operating costs (labor,
overhead) versus other
locations in China
*Expected wage and price
inflation
*Expected currency
appreciation
*Raw material import duties
are high
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Chosen
Location
in
Malaysia
Chosen
Location
In China
Table 7 - Benefits & Risks for the India, Thailand, & Singapore Locations
Operating Capabilties
Ability to Meet Regulatory
& Government
Requirements
Political & Environmental
Stablity Cost Implications
'Existing presence for the *No major issues identified *No major issues identified *Leverage infrastructure at
supply Chain Group for the specific location for the specific location the existing site
*Low setup costs (i.e., shell
space exists)
kWeak IP protection *Raw material import duties
"Current suppliers do not are high
iave local manufacturing *Expected price inflation
ocations
"Only one contract sterilizer
dentified
'Minimal additional space
:or other product lines
>eyond Product Line B
OSome suppliers have *No major issues identified *Current government has *Lower operating costs
ocations (e.g., sterilization for the specific location strong support (i.e. political (labor, overhead)
;ontractors) stability)
"No existing presence for *Potential flooding in *High setup costs (capital
he Supply Chain Group certain regions project)
"Only one contract sterilizer *Political issues in the past
dentified
"Weak IP protection
"Potential language barrier
"Life science industry *No major issues identified *No major issues identified *Location next to the
-luster for the specific location for the specific location regional distribution center
"Strong IP protection *Potential long-term tax
"Minimal cultural issues advantages
"No existing presence for *figh operating costs (labor,
he Supply Chain Group overhead) versus other
"No sterilization contractors locations
dentified *High setup costs (capital
I project)
6.3 Evaluating How the Supply Chain Should Be Organized
As part of the methodology, the next step is to decide how the supply chain operations for
manufacturing Product Line B would be designed. The option to outsource all manufacturing operations
was ruled out due to the following reasons:
1. Intellectual property rights associated with Process Technology A
2. High profit margins for the product line in general
3. New pipeline products with uncertain demand profiles
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Location
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Once that decision is made (typically as part of the business process), the current supply chain can be
evaluated to determine what is required for all unit operations in the manufacturing process. This
information can then be used to develop the supply chains and project costs for each location. Based on
the locations selected in Chapter 6.2, the supply chains for the following options were developed:
1. Malaysia: Build a "greenfield" site in at a selected location in Malaysia
2. China: Build a new manufacturing facility on an existing campus in China
3. India: Retrofit the current space in an existing facility in India
Each of the elements of the value chain specified in Chapter 3.3 was analyzed in order to develop the
supply chains for each option. The insights gained from the analysis and the supply chain development
overall are presented below.
Procurement & Inbound Logistics
Since suppliers have already been identified for the needed raw materials, the External Operations
Group expected to continue using those suppliers rather than find new local suppliers immediately. This
could change after the new facility has been operating after several years, but it was not accounted for as
part of the case study due to complications around determining which suppliers would change. Since
some of the current suppliers already manufacture these materials in the Asia-Pacific region or have the
capability of doing so, inbound transportation costs could be reduced. The inbound transportation costs
varied under each scenario as part of the decision analysis. For example, all raw materials would need to
be shipped from North America under the pessimistic scenario (i.e., suppliers would not shift
manufacturing locations or change lanes). Further details are provided in Tables 11 and 12 in Appendix
A. All inbound shipping from North America initially would be done via air freight as per the
recommendations of the Transportation and Manufacturing Groups. Although the transportation costs
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would be higher compared to ocean freight, both groups wanted to maintain short lead times for the
required raw materials.
Operations & Technology Development
Figure 14 below provides an illustration of the key steps and unit operations for the full
production process of Product Line B and what is conducted at the current sites in North America (notes:
sites are designated as A and B to maintain confidentiality):
Site A Site B
- Primarily - Lubrication & - Instrument
metals & treatment testing during
plastics assembly
- Some raw - Pre-packaged
material testing for shipping at
prior to use the end of
assembly
- Automated & - Gamma Combined
manual Irradiation shipments to
packaging regional
* Labels printed, distribution
inserted and/or centers
applied
Figure 14 - Overview of the Current Supply Chain for Product Line B
Two sites are currently used to execute the full manufacturing process. In-transit transportation is
completed with truck shipments from Site A to Site B, and the travel time is approximately 5 hours. For
the selected locations in the Asia-Pacific region, the new model integrated the packaging and assembly
operations at one site, as opposed to using two separate sites, and utilized a sterilization contractor instead
of building the capabilities in-house. The packaged products would be transported to the sterilization
contractor via truck. Not only would this save on capital expenditure (i.e., not investing in a sterilization
facility) but it also reflects the current viewpoint of the Supply Chain Group regarding sterilization
process technology. As part of a separate project, the Manufacturing, External Operations, and
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Manufacturing Engineering Groups are working together to identify and utilize contractors for
sterilization activities that are not considered a core process technology.
To avoid additional development costs, it was decided that the unit operations at the Asia-Pacific
locations should be fully replicated based on the existing systems as opposed to modifying the processes
specifically for each location. This means that the SKUs associated with Product Line B would be
manufactured according to the same processes with identical equipment. This is a significant advantage
for product registration in each of the Asia-Pacific countries served because the regulatory authorities
could require further validation testing if process modifications are made. This would add an additional
three to six months, as estimated by the Manufacturing Engineering Group, to the overall project timeline.
Moreover, if the manufacturing processes are identical, it becomes easier to troubleshoot equipment
problems and make process improvements at both the North American and the Asia-Pacific locations.
A full production lot for both the instruments and the consumable components can be currently
produced within 24 hours for almost every SKU at Site A. This includes material preparation, assembly,
testing, and packaging. Production yield rates are typically above 95% for all of the manufacturing lines
as well. Since the same type of equipment is being used, in addition to such high productivity levels for
these manufacturing lines currently, the Engineering Group estimates that 90% of the global demand for
Product Line B could be handled with the same production lines included in the new facility. However,
the labor force would need to be significantly increased in order to handle the scale required to meet 90%
of the global demand.
Outbound Logistics
As part of the current supply chain, all finished goods are shipped from North America to the
regional distribution center in Singapore via air freight. Similarly to decisions around inbound freight, the
Manufacturing and Transportation Groups wanted to minimize the lead times for Product Line B to
customers. Both groups recommended using air freight to transport finished goods from China and India
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to the regional distribution center. On the other hand, for the selected location in Malaysia, finished goods
would be shipped via truck to the regional distribution center. In addition to being less expensive than by
using air freight, the difference in lead times is minimal (i.e., a few hours).
Firm Infrastructure & Human Resource Management
As mentioned before, the Supply Chain Group has existing manufacturing operations in India and
China. Therefore, developing capabilities in both locations would meet the group leadership's desire for a
campus approach. The Malaysia option, on the other hand, is considered a "greenfield" site since there is
no existing infrastructure for the Supply Chain Group. This means that the group would need to build the
required infrastructure from scratch (e.g., purchase land, hire a new labor force, install new information
technology (IT) systems). Hence, the project costs would be higher compared to the other options.
Though, as referenced in Table 6 in Chapter 6.2, the Supply Chain Group can leverage the experience of
other another group within the Supply Chain Division that has a presence in Malaysia.
With respect to long-term growth opportunities at the selected Asia-Pacific locations, both the
China and Malaysia options have ample growth capacity to accommodate new product lines at some point
in the future. On the other hand, the India option has limited capacity beyond what is required to
manufacture Product Line B. This is because the existing facility only has enough space for the
equipment required for manufacturing that product line. If the Supply Chain Group wanted to expand its
manufacturing capabilities in India beyond those required for Product Line B (i.e., adding additional
product lines in the future), it would need to build a new facility. Although this does not affect the
analysis performed as part of this case study, it would be a major consideration if other product lines were
identified as sourcing candidates during the "What" phase (only Product Line B was identified).
With the proposed supply chain and locations identified, estimates for the potential project cost
were gathered with help from various experts across Company X. Table 8 provides breakdown of the one-
time project costs for each of the locations (note: all costs are in U.S. Dollars and rounded):
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Table 8 - Overview of Project Costs for Each Location
Malaysia China India
Land Ownership $8,850,000.00 $- $-
Construction $18,400,000.00 $15,650,000.00 $4,100,000.00
IT Infrastructure $9,000,000.00 $9,000,000.00 $9,000,000.00
Process Equipment $23,500,000.00 $23,500,000.00 $23,500,000.00
Construction Logistics $1,200,000.00 $1,200,000.00 $1,200,000.00
Engineering Services $5,000,000.00 $5,000,000.00 $5,000,000.00
Company X Services $5,000,000.00 $5,000,000.00 $5,000,000.00
Commissioning & Validation $500,000.00 $500,000.00 $500,000.00
Regulatory Affairs $200,000.00 $1,500,000.00 $200,000.00
TOTAL $71,650,000.00 $61,350,000.00 $48,500,000.00
The Malaysia option carries the highest cost since it is a "greenfield" project. On the other hand, since the
India option involves retrofitting an existing space, the costs are expected to be lower. As mentioned
earlier, no engineering modifications would be required for the North American operations (Sites A & B).
Site A could instead add an additional shift to meet the increased demands, assuming that the forecasted
scenario occurs, for SKUs of Product Line B. Site B already has the capacity and labor to handle the
additional demand. The Finance Group estimates that it would cost an additional $500K per year in
operating costs (labor and overhead) to add an additional shift at Site A to meet that demand. However,
Company X would continue to single-source Product Line B. This is further evaluated as part of the
decision tree analysis in Chapter 6.4.
The facility design for each of the three locations includes all the required assembly lines and
material preparation equipment that would be required to support demand for all SKUs of Product Line B
in the Asia-Pacific region. The Operations & Technology Development section above includes details
regarding the decisions made for the specific unit operations. The decision tree analysis accounts for the
additional capacity available when evaluating a potential failure in the supply chain. Using the results
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from the operations analysis and project cost estimates, decision analysis tools can be applied to
determine which of the scenarios represents the best path forward for Company X.
6.4 Decision Analysis Results
Appendix B includes all of the calculations for each of the three decision analyses completed. The
following options were analyzed with the decision analysis tools (total landed cost analysis, NPV
analysis, and decision tree analysis) to determine if there was a strong financial case for manufacturing
Product Line B in the Asia-Pacific region:
1. Malaysia: Establish a manufacturing presence at a selected location in Malaysia
2. China: Build a new manufacturing facility on an existing campus in China
3. India: Retrofit the current space in an existing facility in India
4. North America: Continue to ship product to the Asia-Pacific region from the existing site(s)
Overall, the most cost-effective option is to continue meeting regional demand for Product Line B with
the current North American operations versus establishing a manufacturing location in the Asia-Pacific
region. This was confirmed by the results from all of the decision analyses. The results for each analysis
are detailed in this section.
Landed Cost Analysis Results
The total landed costs from each manufacturing location to the regional distribution center in
2019 was determined as part of this analysis. The year 2019 was chosen because of the time required to
complete the required the various capital projects and the availability of sales forecasts up to that point.
For Company X, this year will change since a new seven-year sales forecast is created annually (e.g., if
the analysis were conducted in 2013, 2020 would be the year to evaluate the costs). The total landed cost
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includes all associated manufacturing and supply chain costs as outlined in the "How" phase. Figure 15
illustrates how the costs varied between the three scenarios (note: the term "box" is used to describe the
typical selling size for various SKUs of Product Line B):
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aliii-China
India
m-North America
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Scenario Evaluated
Pessimistic
Figure 15 - Total Landed Costs for Each Scenario Evaluated
We see that the current North American operation maintains the lowest total landed cost in the realistic
and pessimistic scenarios while Malaysia has the lowest total landed cost in the optimistic scenario. On
the other hand, China has the highest total landed cost in all scenarios, even with a significant percentage
of expected sales. One of the main reasons that the North America option has a lower total landed cost is
the fact that there are sunk costs at the existing sites. Much of the equipment and facility depreciation
costs, which are fixed costs, have already been incurred. On the other hand, with the new construction and
equipment installations required for options in the Asia-Pacific options, those locations would incur
higher depreciation costs in 2019.
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The full breakdown for the total landed costs cannot be given in order to further maintain the
confidentiality of proprietary information for Company X. However, the following is an overview of
those results for all three scenarios:
e Direct labor accounts for between 3% (Malaysia, India, North America) and 9% (China) of the
total landed costs. This is not representative of the typical cost structures for other medical
devices sold by Company X. Moreover, it demonstrates the higher relative labor costs in China as
compared to the other locations. The manufacturing location in China is an area where the labor
costs are much higher than the average labor costs for the rest of the country. In fact, the expected
labor costs in this area are higher than those of Site A, which benefits from an area with low labor
costs, in North America.
- Freight costs, both inbound and outbound combined, account for between 4% (Malaysia, North
America) and 8% (China) of the total landed costs. This is in line with some of the other device
cost structures for Company X. In addition, it highlights the higher relative transportation costs to
and from China.
* Overhead costs are the second-largest costs behind material costs. As discussed before., this is
primarily attributed to the depreciation costs at each location.
- Expected duties and import taxes make up between 11% and 23% of the total landed costs,
depending on the location and the scenario. Since the Malaysia option does not have any duties or
taxes on raw material imports as per the allowed incentives by the government, this provides a
significant advantage. Moreover, if free trade agreements are satisfied, the expected costs are
reduced even further. The sensitivity analysis in Chapter 6.5 provides further details as to what
the probability should be in order for the Malaysia option to have the same total landed cost as the
North America option.
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NPV Analysis Results
Details regarding the NPV analysis can be found in Appendix B. Figure 16 shows the NPV for
each new manufacturing locations evaluated under the three scenarios (note: the North America option is
not included because no facility or engineering modifications are actually required to increase output for
Product Line B):
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Figure 16 - NPV Results for Each Location Evaluated
We see that the India option has the highest NPV in all three scenarios. This is due to the fact that the
India option has the lowest one-time project costs of the three Asia-Pacific locations as discussed in the
Firm Infrastructure & Human Resource Management section of Chapter 6.3. However, as mentioned in
the same section, the India option does not allow for expansion opportunities beyond Product Line B as
would the Malaysia and China options. A new manufacturing facility would need to be built in India if
additional product lines were to be manufactured in the country.
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The NPV range, between the optimistic and pessimistic scenarios, is relatively similar for all
three of the locations. Of the three options in the realistic scenario, the expansion in China is the only one
that has a negative NPV. This is due in large part to the higher operating costs overall and the time
required for conducting the mandatory clinical trial that results in an increased project timeline. Appendix
A provides further insights into what changes to the risk factors and uncertainties could yield a positive
NPV.
Decision Tree Analysis Results
The decision tree analysis examines the benefits and risks of having a new manufacturing
location for Product Line B in the global network for the Supply Chain Group. The NPV values of the
Asia-Pacific options were compared against the current operations in North America. Based on the
expected capacity requirements and taking a conservative approach (i.e., uncertainty regarding whether
the sales forecast would be achieved), the Supply Chain Strategy Group looked into the option of adding
an additional shift to meet future demand. Adding an additional shift (approximately $500K per year) at
Site A is cheaper than expanding in a new location. However, products will continue to be single-sourced,
which is seen as a significant risk by senior leaders of the subsidiary.
Working with the Supply Chain Strategy Group, estimates were gathered to determine the
probability of plant failure within the NPV time horizon (10 years). Furthermore, the group was able to
help in estimating the probability of a major failure (i.e., not able to manufacture for at least 1 year)
versus a minor failure (i.e., not able to manufacture for at least 3 months). A major failure includes issues
such as a major product recall or a hazardous incident (e.g., a plant fire), and a minor failure could be
attributed to a minor product recall or an equipment failure. Multiple failures within the same time
horizon were not accounted for in this analysis as per the Supply Chain Strategy Group's
recommendation. The team also estimated that it would cost an additional $75M to address an issue
relating to a major failure and $30M to fix one relating to a minor failure. Appendix B includes a
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breakdown of the applied decision tree and the values. Table 9 shows the expected outcomes for this
analysis:
Table 9 - Outcomes from the Decision Tree Analysis
Options Analyzed Expected Value
1 - Expand in Malaysia $27,699,001.23
2 - Expand in China ($19,586,897.14)
3 - Expand in India $54,299,664.35
4 - Continue with North American Operations $69,939,529.77
We see that it is initially more favorable to continue manufacturing at the location in North America (i.e..
adding another shift) as opposed to expanding in any of the Asia-Pacific locations, thereby providing for
dual sourcing. Of the three expansion options, the expansion in India was favored because this option had
the highest NPV values in every scenario (optimistic, realistic, and pessimistic). Along the same lines, the
expected value for the expansion in China is negative because of the negative NPV values in the realistic
and pessimistic scenarios. It is important to note that this evaluation only considers expansion options for
Product Line B and no other product lines. The expected value of an expansion option would increase if
other product lines were included in the future. Chapter 6.5 includes the sensitivity analysis conducted in
order to determine when it would be more favorable for regional expansion.
6.5 Sensitivity Analysis for the Results
Although the results from the decision analysis suggest that it is preferable to continue shipping
SKUs of Product Line B manufactured in North America to the Asia-Pacific region versus building a new
manufacturing location in the region, it is worthwhile to determine how the decision could change as risk
factors and other uncertainties are varied. A sensitivity analysis was conducted for this reason. The focus
of the sensitivity analysis was on the landed cost and the decision tree results. For the landed costs, the
values for all other risk factors and uncertainties were those identified for the realistic scenario.
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Sales Forecast Variation
Figure 17 illustrates how the total landed cost changes as the sales forecast varies by changing the
scaling factor ("F") in the equation used to calculate the sales growth rate (see the Revenue section of
Appendix A for further details):
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Figure 17 - Total Landed Cost Versus Changes to the Sales Forecast
We see that a significant increase in sales is required in order for the Asia-Pacific manufacturing locations
to achieve a lower total landed cost in one of the expansion options. For example, we would need a 45.9%
increase above the current sales forecast (assuming 100% satisfied, i.e., the value used for the optimistic
scenario) in order for the Malaysia option to be competitive with the current North American operations
As it is, the expected sales forecast change determined for the realistic scenario is 25% lower than the
current sales forecast (i.e., 75% of the original forecast) based on the input from the Financial and
Commercial Groups at Company X.
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Based on the breakdown for the total landed costs between the Malaysia and North America
options, the expected costs for import duties and taxes become greater for the North America option as
demand increases (note: the actual breakdown cannot be revealed to maintain confidentiality of
proprietary information for Company X). The Transportation Group confirmed that several countries in
the Asia-Pacific region charge higher rates for products shipped from North America compared to
products shipped from Malaysia. For the China and India options to be competitive with the North
America option in terms of total landed cost, the change in the sales forecast would need to be much
greater than 200% (i.e., essentially more than double the growth rates of the current forecast). The
Commercial Group commented that this type of growth for an existing product line that has been sold in
the Asia-Pacific region for several years in unrealistic.
Variation in Import Duties & Taxes
The expected costs for import duties and taxes at each location make up approximately 11% to
23%, depending on the location and the scenario, of the total landed costs for Product Line B. One way
that these costs could be lowered is if the qualification requirements for free trade agreements are met in
various countries across the region. The Transportation Group confirmed that at least 65% to 80% of the
materials used in production must be sourced locally or from vendors of an approved location in order to
meet the requirements for the agreements. Assuming that this can be done, the savings will have a major
impact as per Table 10 below (note: total landed costs are shows in total rather than cost per box):
Table 10 - Cost Savings with Free Trade Agreements
No Free Trade Free Trade Agreements
Agreements in Place in Place Potential Savings
Malaysia $ 101,663,027.80 $ 94,846,936.47 $ 6,816,091.33
China $ 126,767,863.92 $ 124,849,836.87 $ 1,918,027.06
India $ 115,265,359.80 $ 115,173,662.11 $ 91,697.70
North America $ 97,140,389.05 $ 97,050,614.71 $ 89,774.33
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The Malaysia option has the highest potential savings of all options reviewed. Treating the cost savings as
an expectation, we would need a 66.4% chance of achieving all savings in order for the total landed cost
of the Malaysia option to be less than the current North American landed cost. However, this endeavor
would require significant changes to the current procurement strategy, since a significant percentage of
raw materials are sourced from the U.S. Changing suppliers and/or convincing current suppliers to
establish manufacturing facilities closer to a new location in the Asia-Pacific region will be difficult. One
senior leader in the External Operations Group commented on the difficulty of successfully doing either
unless extensive resources were available. This is further discussed in Chapter 7 as part the further
considerations going forward.
Variation in Currency Depreciation
In this analysis, the effects of long-term currency changes were evaluated. Although none of the
expansion options will be favored if the local currency appreciates versus the U.S. Dollar, it is worthwhile
to review the scenarios to determine if any options become favored with currency depreciation. Figure 18
shows how the total landed costs would change as a result of long-term currency changes at each of the
Asia-Pacific options:
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Figure 18 - Total Landed Cost Versus Changes in Currency Appreciation / Depreciation
We see that the Malaysia option becomes favored if the local currency (Malaysian Ringgit) depreciates
annually by 8.6%. Such a dramatic change is unlikely over the long term, since the Ringgit has
appreciated over the last eight years versus the U.S. Dollar. In addition, the total landed costs for the
China and India options will only reach a total landed cost of approximately $333 with increasing
currency depreciation. This is due to the fact that many of the transactions are completed in U.S. Dollars
rather than the local currency. Moreover, since Company X maintains accounts across the globe and can
pay a certain amount in local currencies (i.e., no immediate need to convert U.S. Dollars), it may be able
to hedge against currency appreciation in certain circumstances.
Variation in Fuel Inflation
Although the Transportation Group confirmed that real freight inflation does not change over
long periods of time, freight prices are still subject to fuel inflation or deflation. However, since freight
only makes up less than 7% of the total landed costs in most cases, any minor changes will not influence
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the total landed costs overall. Figure 19 proves that only a significant change in fuel inflation will yield a
lower landed cost for the Malaysia option:
$750.00
$675.00
$600.00
$525.00 -- - - - -- - -
$4s0.00 --
-20% -10% 0% 10% 20% 30% 40%
Fuel Inflation (CAGR)
"ZMalaysia
0China
India7 -- North America
50% 60% 70%
Figure 19 - Total Landed Costs Versus Changes to Fuel Inflation Rates
Achieving a 45.9% annual fuel inflation rate is unrealistic over the long term. Therefore, we can conclude
that fuel inflation will not influence the decision overall.
Variation in Wage Inflation / Deflation
Similarly to freight costs, both direct and indirect labor do not have a significant impact on the
total landed cost. As a result, increased wage deflation will not change the outcomes as evidenced in
Figure 20 below:
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Figure 20 - Total Landed Cost Versus Changing Wage Inflation / Deflation
Increasing wage inflation rates will still lead to the North America option having the lowest total landed
cost, and wage deflation (i.e., negative wage inflation) itself is uncommon. Moreover, the total landed
costs for the China and India options will plateau even if wage deflation increases beyond 40%. The
Finance Group has never seen wage inflation or deflation hit such extreme rates, so it can be concluded
that wage inflation will not significantly influence any decision made.
Sensitivity Analysis of the Decision Tree
The sensitivity of a variety of uncertainties was reviewed using TreeAgeTM Pro, which is the
software used to create and evaluate the decision tree in this analysis, and Figures 24 - 26 were generated
using the software. First, the probability of achieving the optimistic scenario was varied to see if the
decision would change at certain values. Figure 21 shows that the North America option is favored in
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every case (i.e., the decision does not change for the entire range of scenarios from optimistic to
pessimistic):
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Figure 21 - Expected Value of All Options Versus Changes in the Scenario
In this case, the pessimistic and optimistic scenario probabilities are inversely proportional (e.g., if
probability of the optimistic scenario =1, the probability of the pessimistic scenario = 0). Under the
optimistic scenario, the total demand and revenues for Product Line B are higher. Consequently, if a
failure were to occur within the existing North American operations in this scenario, the revenue loss
would be higher. This is why the expected values of the Asia-Pacific options increase as the probability of
the optimistic scenario increases. However, with the probabilities confirmed by the Supply Chain Strategy
Group, the North America option has the highest outcome in every scenario.
92
A
*r
,* Opia I- L-qA It Maa
-Option 2 - ExpnI in Chia
a Optioa a - ExpaaM abIa
* Optio 4 - Contine witk North Anerica Opratios
On the other hand, the decision will change as the probability of a failure increases as evidenced
in Figure 22 below:
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Figure 22 - Expected Value of All Options Versus the Changing Failure Probability (Within 1 Year)
We see that an increase in the probability of any type of failure from 1% per year to 3.9% per year (i.e.,
nearly four times greater) will change the decision in favor of the India option This is because expected
revenue loss over the time horizon increases as the probability of a failure increases. In fact, if the
probability of any type of failure were to reach 12%, all of the Asia-Pacific options would have higher
outcomes than the North America option.
Further investigation into the type of failure (major and minor) versus to the probability of any
failure occurring over a ten-year horizon was also conducted. Figure 23 shows how the decision changes
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when both factors are varied (note: major and minor failures are inversely proportional in this case, i.e.,
the probability of a major failure = 0 means that the probability of a minor failure =1):
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Figure 23 - Two-Way Sensitivity Analysis of the Failure Probability & Type
A key takeaway from this analysis is that the decision will change when the probability of a major failure
in the current operations within ten years falls below 80%. In addition, the probability of not having a
single failure (minor or major) within ten years must be greater than 95% in order for the North America
option to be recommended versus any of the other expansion options. This is because any potential supply
chain disruption in the current North American operations will result in a revenue loss large enough to
change the outcome in favor of a dual sourcing option (expanding in India in this case).
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Reviewing the overall results for the sensitivity analysis, it is clear that an increased probability of
failure will likely favor an expansion option, which would allow for dual sourcing of Product Line B,
over continuing current operations in North America with an additional shift (i.e., continuing to single-
source Product Line B). This is due to the fact that the potential revenue loss as a result of a failure is
large enough in every scenario (optimistic, realistic, and pessimistic) to change the expected outcome.
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7 Further Considerations & Conclusion
This chapter presents a set of further considerations and concluding remarks based on the thesis
research conducted and the case study. Reviewing the results presented in Chapter 6.4, it is advisable for
the Supply Chain Group to continue sourcing SKUs of Product Line B from North America rather than
expand its manufacturing operations to the Asia-Pacific region. However, this decision would be worth
revisiting if certain factors were to change, specifically an increase in sales beyond the forecast or the
ability to reduce import duties, as confirmed by the sensitivity analysis presented in Chapter 6.5. This
chapter discusses the benefits of applying the methodology on other product lines and the considerations
that would need to be reviewed further with a new product line that is not already being manufactured at
the commercial scale.
Even though the results were not favorable towards regional expansion for the subsidiary
evaluated, there may be other subsidiaries at Company X that could benefit from expanding
manufacturing operations in the region. In addition, other opportunities were identified that could help
both Company X and other medical device manufacturers in developing their manufacturing footprint
strategies.
7.1 Considerations Beyond the Decision Analysis Results & the Case Study
It is important to consider various factors that were not included in the quantitative decision
analysis for Product Line B. The following three examples, which were taken from the case study,
highlight the importance of these factors when making the final decision(s) with respect to a footprint
expansion:
1. Even though the India option has the highest NPV of all the expansion options evaluated,
including Process Technology A as part of the facility's process capabilities could be considered
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a risk based on the country's ability to protect trade secrets (Global Intellectual Property Center,
2012).
2. The India option will not allow for the addition of product lines beyond Product Line B due to
space constraints in the existing facility. In the future, if additional product lines were selected as
candidates for manufacturing in India (i.e., beyond those evaluated as part of the case study) then
a new production facility would need to be constructed in order to do so.
3. Countries in the Asia-Pacific region could adopt a similar policy as Russia has done and require
some level of domestic production in order to sell those products within the country in the future.
If this were to happen in a major growth market (e.g., China), operational and project costs will
become insignificant compared to the lost revenue if the domestic production requirement is not
met.
A business process team will need to evaluate these risks in order to make the best decision possible. The
Supply Chain Strategy Group currently does not currently have a regular, disciplined process with a well-
managed cycle. However, once such a process is established, evaluating these issues on a regular basis
will become much easier. The evaluation would take less time overall, and the data gathered could be
refreshed quarterly instead of being recollected at a later point in time.
Although the decision analyses for the case study suggested that expansion was not as cost-
effective as the North America option, expansion of manufacturing operations could be warranted for
other subsidiaries. In fact, it is possible that the manufacturing of a combination of other product lines in a
certain location may be more cost-effective than the current operations that include shipping products
assembled in another region. Other product lines, beyond those that were assessed as part of this case
study, must be evaluated using the methodology presented in order to determine whether such an
opportunity exists. Further evaluations using the methodology will help to verify the generality and the
applicability to other types of medical devices. On a similar note, it would be worthwhile to test the
methodology on a new product line that the Supply Chain Group has not manufactured before.
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The case study detailed in Chapter 6 illustrates how the methodology can be applied to an
existing product line that is currently being manufactured in another region. However, this methodology
is also applicable to a product line that is not currently manufactured within the company's network. The
criteria for each phase ("What", "'Where", and "How") would still need to be evaluated in the same
fashion. In addition, infrastructure decisions would be very similar to the options presented in the case
study (e.g., building a "greenfield" site in Malaysia, building a new facility at an existing site in China,
and retrofitting an existing space within an existing facility in India). However, there are three factors that
will require further consideration.
First, the evaluation of Process Maturity in the "What" phase will be difficult due to the fact that
is a new product line and there is no commercial production experience. The business process team will
need to rely on manufacturing performance at the clinical trial scale to determine if the new product line
can be successfully manufactured with minimal issues. Second, there is an opportunity to change the
procurement strategy (criteria for the "Where" and "How" phases). The External Operations Group
generally prefers to use the suppliers that were contracted for clinical trial production rather than
switching suppliers, but other medical device manufacturers may be willing to change suppliers in order
to meet their commercial needs. Lastly, there will be scale-up considerations involving modifications
required to produce at the commercial scale that are not applicable at the clinical scale in most
circumstances. This will be part of the Operations & Technology Development evaluation in the "How"
phase. Since this is a new commercial product line, there are no pre-existing product registrations, and
process modifications can be made more easily as a result. As part of the business process, the Subsidiary
Operations Development team member will have the most input for both of these considerations since
they have direct ties to subsidiary R&D.
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7.2 Other Opportunities Relating to Manufacturing Footprint Strategy
Development
In completing this research with Company X, a number of other opportunities were identified that
complement the development of the company's manufacturing footprint strategy in many ways. The
identified opportunities are as follows:
1. Developing a procurement strategy for the Asia-Pacific region
The evaluation of the subsidiary as part of the case study helped in realizing the financial and
operational importance that suppliers have for the subsidiary evaluated (e.g., material costs
account for 53% to 70% of total landed costs, depending on the location and the scenario).
Moreover, some of the key suppliers do not have a manufacturing presence in the Asia-Pacific
region. If the Supply Chain Group intends to further develop its internal and external
manufacturing capabilities in the Asia-Pacific region in general, it must try to convince existing
suppliers to establish a manufacturing presence in the region or it must identify new suppliers to
meet its manufacturing needs. In addition to the increased responsiveness to the Manufacturing
Group's raw material needs, there is the opportunity of reducing the expected import duty costs
by complying with free trade agreements, many of which require local or regional sourcing.
There are three hurdles that cannot be ignored when developing such a procurement strategy - the
resources needed to qualify the new suppliers (cost, time, etc.), ensuring raw material quality with
new suppliers, and maintaining strong relationships with existing suppliers.
2. Optimizing the current global manufacturing network
When reviewing a number of subsidiaries prior to conducting the case study, it became apparent
that certain subsidiaries had far more manufacturing facilities than others within the network of
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the Supply Chain Group. For the supply chains of these subsidiaries, optimizing the current
manufacturing networks prior to making footprint decisions could result in certain expansion
options no longer being required. These network optimizations would be completed prior to
starting the "Where" phase of the methodology once the product is considered a suitable
candidate as part of the "What" phase. If an opportunity exists but is considered comparable with
the potential expansion options in the Asia-Pacific region by the business process team, the
option should be evaluated with the decision analysis tools to determine the best path forward
(e.g., whether it is more cost-effective or beneficial to optimize the network or move forward with
a footprint expansion). Similar to the updates as part of the business process cycle, any significant
changes that are discovered during the quarterly or semiannual updates should be reviewed for
both the expansion and optimization options (assuming that neither is initially selected as
evidenced in the case study presented in Chapter 6).
3. Enhancing the current decision analysis tools
As previously mentioned, the NPV analysis used by the Finance Group at Company X does not
account for certain data that was included as part of the total landed cost analysis (e.g., outbound
freight, estimated import taxes and duties). Both the Finance and Supply Chain Strategy Groups
should consider the possibility of accounting for these costs as part of their standard NPV
analysis. If it becomes difficult to do so, it would be worthwhile for both groups to develop a
standardized approach to the total landed cost analysis, similar to what was completed in this
thesis research, so that the data and their respective uncertainties will be evaluated as part of the
decision making process. In addition, many companies such as Company X have typically
evaluated options under one set of uncertainties. It is important to understand the range of
outcomes and potential influences rather than anchoring on a single value. These companies
could standardize a way of determining this range (e.g., simulation, scenario analysis). It will help
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in understanding the overall risks associated with the various options, which in turn will allow a
team to make the best decision based on the different options.
7.3 Conclusion
This thesis offers a comprehensive, broadly applicable methodology and a rigorous business
process to aid medical device manufacturers in the evaluation of their Asia-Pacific manufacturing
footprint strategies. A case study was also presented in which the methodology was applied to a specific
subsidiary at Company X. Though the decision analysis results suggested that it is more cost-effective for
the Supply Chain Group to continue shipping SKUs of Product Line B from North America to the region
rather than expand its manufacturing operations, the decision criteria should be reviewed regularly in
order to keep abreast of the changing economic, government, and regulatory landscapes. These factors
will be different when dealing with new product lines, but the same methodology can still be applied.
Senior leaders across Company X have consistently highlighted the importance of the Asia
Pacific region, especially the emerging markets, in their medical device long-term growth strategy. The
methodology and the business process presented will allow the company, as well as other medical device
manufacturers, to meet those future needs and be confident that they have made the right decision the first
time.
101
Appendix A: Formulas & Risk Factors Applied
This section outlines all of the risk factors and equations used for the analysis of the subsidiary as detailed
in Chapter 6. Although these equations were developed and applied for Company X, they are potentially
applicable for other manufacturers as well. Each section of this appendix highlights the equations that
were applied as part of the total landed cost analysis and the NPV analysis. Company X considers the
calculations for the NPV analysis and data inputs for the equations (e.g., scaling factors, costs, weights) as
proprietary information. For this reason, details of the associated calculations are not discussed in-depth.
The last section provides an overview of all of the uncertainties used in the three scenarios as well as the
sources for that data. The following is a list of general items that apply to each section:
Many of the data points are dependent on the applicable year. The term "t" represents the year for
that data point. 2013 is represented as t = 0, and t increases incrementally by year (e.g., 2014,
t= 1).
' Unless otherwise stated, all costs are in U.S. dollars. This is because a majority of the transactions
are completed in the U.S. with international brokers. This was confirmed with the groups that
handle these expenses as part of the analysis with Company X.
e Currency fluctuations are very difficult to predict over long periods of time and are dependent on
a variety of factors (interest rates, exports, etc.). For the case study completed with Company X, it
was assumed that the valuation would generally increase or decrease over a long period of time.
The term "currency depreciation" refers to this expected currency change over time. If the value
is negative, it means that the local foreign currency will appreciate versus the U.S. dollar for that
period. Tables 11 and 12 includes the values and sources that were determined as part of the
analysis. Various companies may use tactics to hedge against currency fluctuations and avoid
these additional costs.
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- Various inflation factors are described in this appendix. Unless otherwise stated, nominal
inflation is defined by the following equation:
Nominal Inflation = Real Inflation + Price Inflation
Price inflation is dependent on the type of cost and where the transaction takes place. This is
specified in each section where the formula is applicable.
The relevant equations and reasoning are separated into the following sections in this appendix: Revenue,
Demand, Weight and Volume, Material Costs, Labor Costs (Direct and Indirect), Additional Overhead
Costs, Transportation Costs, Costs for Import Duties and Associated Taxes, and Inventory Holding Costs.
Revenue
The current revenues for each product line and their annual growth rates must be given in order to
determine the future revenues. The growth rates can be modified using the following equation:
sales growth rate(t) = E [growth rate(t)] x F
"F" is the scaling factor for modifying the growth rate for each of the scenarios, and "E[growth rate(t)]" is
the given annual growth rate. As an example to show the equation works, if the sales growth rate is
expected to be 50% of the expected growth rate for a certain scenario, all of the values are shifted lower
by 50% of the expected value (i.e., 2% growth rate will become 1%, and a -4% growth rate will become
-6%). Using the modified growth rate, the following equation is then applied to determine the revenue for
each year:
Revenue(t) = Revenue(t - 1) x [1 + sales growth rate(t)]
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Revenues for the case study described in Chapter 6 were stated in U.S. dollars, so no modifications were
required. Both equations listed above can be applied to the Global and Asia-Pacific (APAC) revenue data
as needed.
Demand
This analysis required the current demand volumes to be calculated for the various product lines. Working
with the Production Planning Group, which is part of the Supply Chain Group, it was discovered that the
demand growth rates were not equal to the sales growth rates due to pricing changes and product
cannibalization (i.e., certain SKUs would replace the sale of others). The following equation can be
applied:
demand growth rate (t) = sales growth rate (t) x X
"X" is the scaling factor to account for the expected inequality. To determine this factor for Product Line
B, previous demand volumes were compared to the revenues from 2009 to 2011 Similarly to determining
the yearly revenues, the demand volumes can be calculated using the following equation:
Demand(t) = Demand(t - 1) x [1 + demand growth rate(t)]
Demand, in this case, is the number of boxes for the product line analyzed. For the product lines
evaluated as part of the case study, certain breakdowns were required between different products within a
product line (e.g., surgical instruments and consumable components for Product Line B). Historical data
for sales and demand volume between 2009 and 2011 was analyzed to determine the projected breakdown
for those product lines. At Company X, the demand data was only given as global demand. Therefore, the
data needed to be translated to the regional demand for APAC. To do that, further evaluation was
completed of previous APAC and global demand volumes, and a relationship was found based on the
APAC revenue percentage. The following equation illustrates this relationship:
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APAC Demand(t) = P x x Global Demand(t)
Global Revenue(t) G
"P" is the scaling factor that was applied to determine the APAC demand. If P < 1, it means that there is a
pricing difference that generates less demand volume in APAC (vice-versa if P > 1).
These demand volumes did not initially include any inventory changes. The following equation can be
used to determine the change in inventory for each year:
A APAC Inventory(t) = T x [APAC Demand(t) - APAC Demand(t - 1)]
"T" is the expected inventory supply in terms of years. Generally speaking. Company X tries to maintain
one month's supply of Product Line B in finished goods inventory. Total demand for the APAC region in
a given year can then be determined using the following equation:
Total Demand(t) = APAC Demand(t) + A APAC Inventory(t)
As mentioned before, the analysis discussed in Chapter 6 only accounted for demand in the APAC region
and thus equals to the total demand satisfied by the new location.
Weight & Volume
Weight and Volume are required to estimate the sterilization and shipping costs. Data for the actual
weight (lb.) and volume (in) for each SKU of Product Line B was analyzed to determine the overall
weighted average that can be used for the calculations. Due to transportation requirements, the
dimensional weight needed to be calculated first using the following equation:
Unit Actual Weight(t) 1 kgUnit Dimensional W eight Ct) = x .25 bx Z
166 - 2.205 lb
lb
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"Z" is a scaling factor applied to account for the space needed for transportation packaging. The number
166 represents the expected volume-to-weight ratio that would be applied to determine the dimensional
weight. The Transportation Group confirmed that the transportation costs would be highest between the
dimensional and actual weights as shown in the following equation:
Unit Chargeable Weight(t) = MAX[Unit Dimensional Weight(t), Unit Actual Weight(t)]
For every SKU in Product Line B, the dimensional weight equaled the chargeable weight. This was not
always the case for the other product lines evaluated. Using the chargeable weight, the total weight that
would be charged for transportation was determined with the following equation:
Total Weight(t) = Unit Chargeable Weight(t) x Total Demand(t)
In a similar fashion, the volume required for sterilization can be determined using the following equation:
Sterilizeable Volume(t) = Unit Dimensional Weight(t) x Total Demand(t) x S
"S" is a scaling factor used to represent the additional volume taken up by the "tote" (i.e., set of boxes for
sterilization). These totes increase the sterilizable volume beyond that required for the packaged devices
themselves.
Material Costs
To determine the material costs for each year, we need to understand what the expected material costs
will be per unit of demand. For the analysis, the weighted average of the material costs for each SKU was
determine through available cost accounting data from the Finance Group. The following equation cab
then be applied:
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Total Material Costs(t)
= E[Material Cost] x Total Demand(t) x [1 + material cost growth rate]t
The "material cost growth rate" is a risk factor that accounts for the potential increase or decrease in
material costs over time. Material costs could increase due to price inflation or scarcity of materials, but
they could also decrease due to price competition. Table 11 in this section includes the anticipated growth
rate in each of the scenarios. For all locations, the material costs were anticipated to be the same.
However, raw material transportation costs will differ depending on the manufacturing location being
evaluated.
Labor Costs (Direct & Indirect)
Both direct and indirect labor costs can be calculated using the following equation:
Labor Cost(t)
= Labor Number(t) x Avg. Salary x [1 + nominal wage inf lation]t
x [1 - currency depreciation]t
"Labor Number" represents the expected number of operators or employees for the year. For the analysis,
labor costs were variable based on the production volume. However, they do not increase at the same rate.
Furthermore, indirect labor costs are considered an overhead cost at Company C. The Finance Group
maintains the average salary calculations for both direct and indirect labor. In addition, the company
maintains its own estimates for real wage inflation as well as country-specific inflation per Table. For the
landed cost calculations specific to the current operations in North America, real wage inflation was
assumed to be negligible based on input from the Finance Group. The labor costs would also be affected
by currency appreciation or depreciation at each location since payments would be made in the local
currencies as opposed to U.S. Dollars.
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Additional Overhead Costs
There are five components in the total overhead costs that were analyzed: indirect labor, inbound / in-
transit transportation, depreciation, sterilization costs, and additional manufacturing burden. The Finance
Group at Company X considers these components as overhead expenses, and all of the overhead costs in
this case are variable except for the depreciation. Details for indirect labor and inbound / in-transit
transportation costs are respectively given in the "Labor Costs" and "Transportation Costs" sections of
this appendix.
To account for the depreciation costs as part of the landed cost analysis, the expected depreciation amount
was calculated using a 10-year straight-line assumption. The value was based primarily on the equipment
and machinery costs. For the NPV analysis completed by the Finance Group, a different method was used
to calculate the depreciation expenses. Depreciation is not affected by inflation or currency depreciation
in this type of analysis.
To determine the total sterilization costs, the following equation can be used:
Total Sterilization Costs(t) = Sterilizeable Volume(t) x Sterilization Cost
Sterilization Cost is a pre-negotiated price that Company X has established with various sterilization
contractors. Factors that influence this price include lead-time requirements, expected volumes for
sterilization, and market competition. For the case study, the sterilization cost was assumed to be a
constant value based on the information provided by the External Operations Group.
Additional manufacturing burden (a variable overhead cost) accounts for all of the other factors affecting
overhead (e.g., utilities, lubrication, maintenance), and they are subject to both price inflation and
currency depreciation. The Finance Group keeps track of these costs on a regular basis. The following
equation can be applied based to calculate the year-over-year costs:
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Add'l Mfg Burden(t)
= Add'l Mfg Burden(t - 1) x [1 + price inflation] x [1 - currency depreciation]
"Price inflation" is dependent on the manufacturing location and is a risk factor that varies in each
scenario. Table I I in this appendix provides the values that were used as part of the case study.
Transportation Costs
Since manufacturers will have different expectations regarding transportation (e.g., modes, lead times),
this section shows how the costs were calculated within the Transportation Group at Company X.
Although the Finance Group considers inbound / in-transit transportation to be part of the overhead costs,
outbound transportation costs are not part of the overhead costs for the product lines analyzed.
A combination of airfreight and truck shipping are used for moving finished goods, work-in-progress
parts, and raw materials associated with Product Line B along pre-determined lanes. As part of the
analysis, transportation costs were found to be dependent on the weight or the number of shipments. To
calculate the number of shipments, the following equation can be used:
T otal Demand(t)
Total Shipments(t) = BB
"'B" represents the number of boxes that are carried in a shipment. It is important to note that shipment
sizes in the U.S. differed from those in APAC due to different truck and carton sizes (i.e., different values
for "B" were applied in each situation).
The next step is to determine the expected freight inflation for both methods of transportation (note: fuel
inflation is separate from freight inflation). Based on the data provided by the Transportation Group, real
freight inflation did not change over long periods of time (2-3 year periods). Therefore, freight was
assumed to only be dependent on country-specific price inflation. Since the costs are in U.S. dollars, the
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inflation growth rate was equal to the expected U.S. inflation for each scenario. On the other hand, fuel
inflation was expected to change over time. The following equation can be applied to determine the total
airfreight costs:
Total Airfreight Costs(t)
= Weight Based Costs(i) - Fuel Costs) x Total Weight(t)J
+ Shipment Based Costs(i)) x Total Shipments(t)II x [1 + price inflation]t
+ (Fuel Costs x [1 + nominal oil price growth rate]t )
Weight-base costs, which are dependent on the weight of the products being shipped, include the
following (represented by i): airfreight, security, x-ray, pick-up, handling, transfers, and delivery. Fuel
costs are also considered a weight-based cost, but they will also increase by the real growth rate of fuel
prices. The Transportation Group confirmed that the real growth rate of fuel prices is approximately equal
to the real growth rate of oil prices. Thus, the nominal oil price growth rate, which is the real oil price
growth rate plus the U.S. inflation rate, was applied to the fuel costs. Table 11 includes the real growth
rate of oil prices for each scenario. Shipment-based costs, which are dependent on the number of
shipments and are also represented by i, include document handling, document clearing, and broker fees.
For truck-based shipping, fuel costs cannot be separated from other costs. In addition, the costs are based
solely on the number of shipments as opposed to weight. In light of this information, the following
equation should be applied to determine the total inflation for truck-based shipments:
modified freight inf lation = (60% x price inflation) + (40% x nominal oil inf lation)
Experts in the Transportation Group at Company X confirmed these percentages (60% and 40%). As
mentioned before, since real freight inflation did not change over time, the expected U.S. inflation rate
was used. The total shipping costs for truck freight can be determined with the following equation:
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Total Truck Shipping Costs(t)
Truck Costs
= Total Shipments (t) x x [1 + modified freight inflation]t
Shipment
Since the primary modes of transportation are air and truck, the following equation can then be used to
determine the total transportation costs for an identified lane.
Total Transportation Costs(t) = Total Airfreight Costs(t) + Total Truck Shipping Costs(t)
This equation can be directly applied for the outbound and in-transit lanes to determine those
transportation costs. If another medical device manufacturer did use ocean freight as a means of
transportation, those costs would also need to factor in the "Total Transportation Costs(t)" equation.
As part of this analysis, assumptions were made for each scenario regarding the possibility of utilizing
local sourcing or having current suppliers produce raw materials closer to the new manufacturing
location. In either of those situations, the raw material transportation costs would change. The following
equation can be used:
Total Raw Material Inbound Transportation Costs(t)
= R x Total Inbound Transportation Costs(t)
"R" is the scalable factor for the anticipated inbound transportation costs. This is considered an
uncertainty, and further details can be found in Tables 11 and 12. Inbound Transportation Costs can be
separated into truck and airfreight as needed for other calculations such as raw material import duties and
taxes.
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Expected Costs for Import Duties & Associated Taxes
Import duties and taxes differ by country and by manufacturing location, and they can differ for the same
country if certain criteria are met (e.g., meeting the procurement requirements for free trade agreements).
For this reason, the demand volume needs to be identified by country or sub-region whenever possible.
For the case study presented in this thesis, demand volumes were calculated for Japan, China, and India,
which in total make up more than 50% of revenue in the region, based on the sales forecasts for each
country using the formulas described earlier in this appendix. The remaining volume was designated as
"Other APAC", and the duty and tax rates used to estimate the expected costs were taken as the average
of the rates based on the guidance of the experts within the Transportation Group. The first step in
determining the associated costs is to calculate the "Cost Plus Freight" value for each country. The
following equation was developed and applied:
Finished Goods Cost Plus Freight(t)
Standard Cost per Uni Total Outbound Freight x Country Demand (t)
# of units
"'Standard Cost per Unit" is the per-unit manufacturing cost (i.e., materials, labor, and overhead
combined). For this analysis, outbound freight costs were simplified and considered equal to the freight
costs from the manufacturing location to the regional distribution center in Singapore, where all products
distributed by Company X throughout the APAC region are initially sent. This is a significant
simplification that was made with the guidance of the Transportation Group for this analysis. The next
step is to determine the associated duties and import taxes for each location. It is important to note that
certain locations may have import duties but no additional taxes or other fees and vice-versa. For the case
study presented in this thesis, the Transportation Group was able to provide this information based on the
Harmonized System Code for Product Line B. The associated costs can then be calculated using the
equation below:
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Total Finished Goods Import Duties & Taxes(t)
= Finished Goods Cost Plus Freight(i, t) x (Duty(i) + Import Tax(i) + Other Fees(i))
The term "i" represents each country or sub-region where products are being distributed. For this analysis,
the rates for the duties, import taxes, and additional fees depended on whether or not Company X was
able to meet free trade agreements for the specific location. If so, the rates are much lower. The
Transportation Group was not confident that free trade agreements could be easily met due to the current
raw material procurement strategy for Product Line B. Consequently, the scenario for free trade
agreements being satisfied was only applicable in the optimistic scenario. The rates can also change
without ample notice, but this was not applied in the analysis. However, this is something that the Supply
Chain Strategy Group at Company X should monitor as part of the business process.
Import duties and associated taxes for raw materials were calculated in a similar manner. First, the "Cost
Plus Freight" for the raw materials needs to be determined using the following equation:
Raw Materials Cost Plus Freight(t)
= (Total Material Costs(t) x R) + Total Raw Material Inbound Airfreight Costs(t)
Only imported materials are subject to duties and taxes, hence the need for the scalable factor "R"
(defined in the "Transportation Costs" section). For the analysis, since truck shipping costs were minimal
in comparison to the airfreight costs at each of the manufacturing locations, they were not included. If
they were more significant, they would need to be included as well.
Total Raw Materials Import Duties & Taxes(t)
= Raw Materials Cost Plus Freight(t) x (Duty(i) + Import Tax(i) + Other Fees(i))
The term "i" refers to the manufacturing location. In this analysis, the Transportation Group confirmed
that there were no immediate rate changes even if free trade agreements were satisfied in Malaysia,
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China, and India. Of the three countries in the APAC region chosen for further evaluation, Malaysia is the
only country of the three evaluated that does not charge any import duties or taxes on raw materials for
medical device manufacturers This analysis assumes that the requirements for Pioneer Status are met
(Ernst & Young, 2012). The Transportation Group also confirmed that there are no raw material import
duties and taxes for the North American operations based on existing agreements.
Inventory Carrying Costs
The inventory carrying costs must be included in the decision analysis, and these costs should be applied
for raw materials, work-in-progress goods, and finished goods. The carrying costs include the inventory
holding costs and cost of financing as defined by Simchi-Levi (2008). For the case study with Product
Line B, the work-in-progress inventory was not accounted for due to the relatively short time needed for
the assembly process (i.e., 1 day). In addition, since sterilization costs did not have a significant impact on
COGS and the transit time was relatively short (i.e., 1-2 days), the standard cost per unit was applied. The
following equation can be used to calculate the total inventory carrying costs
Inventory Carrying Cost(t)
= [(Raw Material Costs(t)x M) + (Standard Cost per Unit x Total Demand(t)x L)]x c
"'M" is the length of time that raw materials are held prior to assembly, and "L" is the lead time from the
end of mechanical assembly to the arrival at the regional distribution center in Singapore. Both of these
values were measured in days but converted to years for the calculations. The term "c" is the inventory
carrying cost, and this value was ascertained from the Finance Group in Company X as a general
estimate. The Finance Group assumed that the carrying costs would be the same regardless of the
manufacturing location.
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Risk Factors
Table 11 includes all of the risk factors and uncertainties applied for each scenario and each
manufacturing location in this analysis. Table 12 provides the sources and respective notes for the chosen
risk factors and uncertainties.
Table 11 - Risk Factors & Uncertainties for Each Location & Scenario
Malaysia China India North America (Current)
Optimistic Realistic Pessimistic Optimistic Realistic Pessimistic Optimistic Realistic Pessimistic Optimistic Realistic Pessimistic
Asia-Pacific
Sales
Forecast 100.00% 75.00% 50.00% 100.00% 75.00% 50.00% 100.00% 75.00% 50.00% 100.00% 75.00% 50.00%
(regional- &
country-
specific)
Price
1.21% 1.8000 2.39% 2.08% 3.10% 4.12% 5.90% 8.80% 11.70% *equalI 
to the S Inflion Rate
(country- lse ute eo
specific)
Fuel Price
Inflation -0.98% 2.44% 3.76% -0.98% 2.44% 3.76% -0.98% 2.44% 3.76% -0.98% 2.44% 3.76%
(real)
Wage N/A (assumed no real wage inflation
Inflation 0.47% 0.70% 093% 7.17% 10.70% 1423% 0.74% 1.10% 1.46% in the U.S.)
(real)
Currency
Appreciation -0.66% -1.27% -4.89% -2.77% -3.37% -4.13% 2.51% 0.24% -3.09% N/A (all prices in U.S. dollars)
Depreciation,
Project Cost 90.00% 100.00% 120.00% 90.00% 100.00% 120.000% 90.00% 100.00% 120.000% N/A (no additional project required)
Factor
Material 99.00% 100.000 102.00% 99.00% 100.00% 102100% 99.00% 100.00% 102.00% 99.00% 100.0000 102.00%
Cost Factor I
U.S.Price 1.63% 2.80% 3.60% 1.63% 2.80% 3.60% 1.63% 2.80% 3.60% 1.63% 2.80% 3.60%
Inflation
Materials
Freight 50% 75% 100% 50% 750% 1000% 50% 75% 100% N/A (no changes anticipated for
Change current material freight)
Factor
Project
Timeline 3.0 3.5 4.0 4.0 4.5 5.0 3.0 3.5 4.0 N/A (no capital project required)
(years)
No free No free No free No free No free No free No free No free
Import Taxes Free trade tae rde Free trae trade ta Free rae trade a Freemtr trade trade
&ceDutie iplaees agreements agreements agreeme agreements agreements a e agreements agreements in place agreements agreementsScenario in place in place in place in place in place in place in place in place in place
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Table 12 - Sources & Notes for the Chosen Risk Factors & Uncertainties
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Asia-Paciic 
*Defined as scalable factor "F"Sales Company X - discussions with *100% = hit sales forecast as expected, 75%= hit sales forecast by 75%, 50% = hit salesForecast Finance and Commercial forecast by 50% [note: general expectation are that the sales forecast is only met by 75%}
(cgona- &Groups *Sales forecasts already assume inflation, exchange rate fluctuations, etc. (i.e., no
specific) modifications required)
Pie Company X - economic
Inflation research provided to the *Taken as the 67%. 100%, and 133% (optimistic, realistic, and pessimistic respectively)
(Country- Commercial Groups for each country based on the report
specific)
FulPie(U.S. Energy Information
Inflation *Based on the best-case, realistic, and worst-case scenarios as evaluated from 2010 - 2035
(Real) Administration, 2012)
Wage Company X - economic *Taken as the 67%, 100%, and 133% (optimistic, realistic, and pessimistic respectively)Inflation research provided to the for each country based on the report(Real) Commercial Groups__________________________________
Currency
Appreciation (XE Currency Tables, 2012) *Looked at exchange rate data from 2004 - Dec 2012 and calculated the 33rd (optimistic),
50th (realistic), and 67th (pessimistic) percentiles of annual values
Depreciation
Company X- discussion with
Project Cost the Manufacturing and * -10% / +20% (optimisitic and pessimistic respectively) of the calculated project costs in
Factor Manufacturing Engineering Chapter 6
Groups
.Company X - discussion withMaterial the External Supply and *1% decrease per year in material costs (optimistic) and a 2% increase (pessimistic)
Cost Factor Production Planning Groups assumed based ont eh reason discussed in this Appendix ("Material Costs" Section)
U.S. Price (Coin News Media Group, *33rd (optimistic), 50th (realistic), and 67th (pessimistic) percentiles of US price inflation
Inflation 2012) from 1926 - 2011
Materials *Assume material freight costs decrease by 50% (optimistic), by 25% (realistic), and 0%
Freight Company X - discussion with (pessimistic) when establishing the Asia-Pac location;
Change the Production Planning Group *This is due to finding local suppliers or having current suppliers source from APAC
Factor locations
Project Company X - discussion with
Tieline the Supply Chain Strategy *Assume additional year for China due to clinical trial requirements
(years) Group and the subsidiary R&D
Import Taxes *Free trade agreements allow for reduced or no duties to be leveraged on product
& Duties Company X - discussion with exported to that country
ar the Transportation Group *In order to satsify the agreeements, one must show that 65%-80% of raw materials are
Scenario__ I_ Icoming from APAC supplier (acutal percentage depends on the country)
Source Notes
Appendix B: Decision Analysis for Product Line B
This section includes discussions around the landed cost analysis, the NPV analysis, and the decision tree
analysis in Chapter 6.4. 1 developed the templates and frameworks for both the total landed cost and the
decision tree analyses. Company X required the use of their template for the NPV analysis. As mentioned
before, the original data was modified to maintain confidentiality of proprietary information for Company
X. Details for each analysis are included in the separate sections below.
Total Landed Cost Analysis
The results of the total landed cost analysis, including the breakdowns for the options for each scenario
(optimistic, realistic, and pessimistic) cannot be revealed to further maintain confidentiality of proprietary
information for Company X. Table 13 below shows the how the cost breakdowns were reviewed as part
of this analysis:
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Table 13 - Total Landed Cost Breakdown Reviewed in the Case Study
Option (Malaysia, China, India, North America)
Optimistic Realistic Pessimistic
Material Costs
Direct Labor Costs
Overhead Costs
Indirect Labor
Inbound Freight
Sterilization & Transit Freight
Add' Manufacturing Burden
Expected Depreciation
Outbound Freight
Estimated Duties & Import Taxes
Raw Material Import Taxes
Finished Goods Duties & Import Taxes
Total Inventory Carrying Costs
Raw Materials Inventory
Work-in-Progress & Finished Goods Inventory
APAC Total Landed Costs
Number of Boxes Produced / Shipped
APAC Total Landed Cost per Box
Breakdown per Box
Materials
Direct Labor
Overhead (No Freight Included)
Inbound & Outboud Freight
Duties & Import Taxes
Inventory Carrying Costs
Percentage per Box
Materials
Direct Labor
Overhead (No Freight Included)
Inbound & Outboud Freight
Duties & Import Taxes
Inventory Carrying Costs
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All calculations were completed using the modified data set and the equations listed in Appendix A.
Although import taxes and duties are actually paid when the product is shipped to a specific country.
estimates were calculated based on the manufacturing location and the current rates paid by Company X.
The total landed cost calculations for North America were made using the overhead values from the
standard cost data, and detailed breakdowns for sterilization, in-transit freight, depreciation, and
additional manufacturing burden were not available. The Finance Group at Company X provided the
standard cost data used for this analysis.
NPV Analysis
As mentioned in Chapter 6.4, the NPV analysis was completed with help from the Finance Group at
Company X. Both the Supply Chain Strategy and Finance Groups required the use of the company's NPV
template as opposed to creating a separate template for this analysis. This allowed for the NPV results to
be easily compared to other projects being evaluated by the groups at the time. On the other hand, this did
not allow for modifications to projected revenues beyond a specified year. The following is a list of
general highlights from the NPV analysis:
- The NPV analysis can be broken down into the following categories: incremental revenue,
operating expenses (i.e., COGS, SG&A), project costs, and recurring costs (i.e., cost savings or
increases as result of the production shift). Taxes are deducted from the subtotal, and the resulting
annual cash flow is then discounted.
- The calculations are based on the yearly incremental sales in the region. Therefore, as long as the
sum of the project costs, operating costs, and recurring costs are less than the cash flow generated
from sales over the specified time horizon, the NPV value will be positive.
- The applied tax rate was determined after consulting with tax experts within the Finance Group.
Although some of the locations evaluated provide tax incentives that could decrease the effective
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rate, the experts noted that it could change the current tax structures in place, and they did not
recommend any changes to the current structures.
The Finance Group currently does not account for the following as part of its NPV analysis:
outbound freight, import duties and taxes, and associated inventory costs. Consequently, they
were not included. This made it difficult to determine what changes to uncertainties for these
costs could result in a higher NPV for Malaysia or China versus India. This highlights the
importance of using a variety of decision analysis tools, since another tool can be used to identify
and account for these costs.
Further details regarding calculations and tax rates cannot be revealed in order to maintain confidentiality
for Company X.
Decision Tree Analysis
Figures 24, 25, 26, and 27 show the branches of the decision tree for each option (note: the decision tree
was created and analyzed using TreeAgeTM Pro Software, and each figure is a screenshot from the
program):
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Figure 24 - Decision Tree Structure for the Malaysia Option
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Figure 26 - Decision Tree Structure for the India Option
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Figure 27 - Decision Tree Structure for the North America Option
For each option, the probability of each scenario (optimistic, realistic, and pessimistic) occurring was
identified with help from the Supply Chain Strategy Group. Then, the probability of a single failure
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pton3 - EXPa
n India
1-p-mojor-fai ...
occurring was calculated using the probability of an annual failure as well as the probability of that failure
being a major or a minor failure. The Supply Chain Strategy Group was instrumental, once again, in
providing these values for the analysis. If a failure did occur, the expected revenue loss and the cost to
remedy that failure were subtracted from the NPV value, which differed based on the option and the
scenario. As previously mentioned, the NPV values used were calculated with using the standards set by
the Finance Group at Company X.
Table 14 below lists the variables and the probabilities that were used in the decision tree analysis:
Table 14 - Decision Tree Variables & Probabilities
Variabie Name Description Value
p Optimistic Probability of the optimistic scenario 0.25
p_ Realistic Probability of the realistic scenario 0.50
p Pessimistic Probability of the pessimistic scenario 0.25
p failure in year Probability of a failure in 1 year 0.01
p no failure 10 years Probability of no failures within 10 years (1-p failurein_year)^10
p major failure Probaility of a major failure i.e. 1 year revenue loss 0.1
p minor failure Probability of a minor failure i.e. 3 months revenue loss i-p major failure
NPV 0 China China Optimistic NPV 71110634.83
NPVR China China Realistic NPV -20043369.46
NPV P China China Pessimistic NPV -83066806.04
NPV O Malaysia Malaysia Optimistic NPV 130632054.01
NPVRMalaysia Malaysia Realistic NPV 26568660.77
NPV P Malaysia Malaysia Pessimistic NPV -46668692.23
NPV_ 0India Indian Optimistic NPV 155191260.75
NPV R India India Realistic NPV 51592608.73
NPV P India India Pessimistic NPV -14873142.41
NPV 0 NA North America Optimistic NPV 194589332.74
NPVR NA North America Realistic NPV 95152145.42
NPV P NA North America Pessimistic NPV 39153816.76
P PLB RevenueMajor Pessimistic one-year additional revenue for Product Line B 1089908843.07
Fix Major Failure Cost to fix a major failure 75000000
Fix Minor Failure Cost to fix a minor failure 30000000
P PL B RevenueMinor Pessimistic 3-month additional revenue for Product Line B 272477210.77
percentage lost Percentage of revenue that the new site would make up -0.10
R PL B RevenueMajor Realistic one-year additional revenue for Product Line B 932769418.20
R PL B Revenue Minor Realistic 3-month additional revenue for Product Line B 233192354.55
O PL B Revenue Major Optimistic one-year additional revenue for Product Line B 1263074113.51
OPL B Revenue Minor Optimistic 3-month additional revenue for Product Line B 315768528.4
The Supply Chain Strategy Group at Company X reviewed the applied probabilities for this analysis. The
realistic scenario was the most likely to occur when compared to the optimistic and pessimistic scenarios,
hence the differences in these probabilities. The calculations for the expected revenue in case of a failure
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were based on the "Global Minus APAC" sales in 2019. It was assumed that if manufacturing operations
for Product Line B were expanded, the new location would be able to produce a certain amount of
product that would have otherwise been produced at the current North American location, and initial
estimates showed a 90% global revenue recovery for the facility design in all three locations (Malaysia.
China, and India). The recovery costs ($75M for a major failure and $30M for a minor failure) include all
operational changes that are required to support global demand for such an event (e.g.., increased labor,
logistics, project expenses), in addition to the costs required to remedy the issue at the North American
location(s). In the end, the analysis confirmed that it is worth continuing to supply product from North
America as opposed to expanding manufacturing operations in the APAC region.
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